{"info":{"_postman_id":"1e3a07f2-3a37-4d81-ad54-90ecf5f16302","name":"PV/Safety API Documentation","description":"

Authentication:

\n\n","schema":"https://schema.getpostman.com/json/collection/v2.0.0/collection.json","toc":[{"content":"Authentication:","slug":"authentication"}],"owner":"9012901","collectionId":"1e3a07f2-3a37-4d81-ad54-90ecf5f16302","publishedId":"2s93XvWjvq","public":true,"customColor":{"top-bar":"FFFFFF","right-sidebar":"303030","highlight":"FF6C37"},"publishDate":"2024-06-14T16:05:04.000Z"},"item":[{"name":"Authenticate User Session","id":"aa83f9d4-f133-4eaf-94e1-fe84333063f4","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"auth":{"type":"basic","basic":{"basicConfig":[{"key":"username","value":""},{"key":"password","value":""}]},"isInherited":false},"method":"GET","header":[],"body":{"mode":"formdata","formdata":[]},"url":"https://labelae.doctorevidence.com/auth","description":"\n

Response Data:

\n\n","urlObject":{"protocol":"https","path":["auth"],"host":["labelae","doctorevidence","com"],"query":[],"variable":[]}},"response":[{"id":"05a756eb-de5a-4680-8992-05e07c66e72a","name":"Bulk import label metadata","originalRequest":{"method":"GET","header":[],"body":{"mode":"formdata","formdata":[]},"url":"https://labelae.doctorevidence.com/auth"},"status":"OK","code":200,"_postman_previewlanguage":"html","header":[{"key":"Cache-Control","value":"private"},{"key":"Content-Type","value":"text/html; charset=utf-8"},{"key":"Vary","value":"Accept"},{"key":"Server","value":"Microsoft-IIS/8.5"},{"key":"X-StackifyID","value":"V2|4fa2f970-8e20-4a4b-8e22-022aaa8d34ca|C57775|CD6"},{"key":"X-Powered-By","value":"ServiceStack/5.10 NET45 Win32NT/.NET"},{"key":"Access-Control-Allow-Methods","value":"GET, POST, PUT, DELETE, OPTIONS"},{"key":"Access-Control-Allow-Headers","value":"Content-Type, Allow, Authorization, Wait, Accept, X-Requested-With, Put-Default-Position, Put-Before, If-Match, If-None-Match, Content-Range"},{"key":"Access-Control-Allow-Credentials","value":"true"},{"key":"Access-Control-Expose-Headers","value":"Content-Range"},{"key":"X-AspNet-Version","value":"4.0.30319"},{"key":"Set-Cookie","value":"ss-id=Fh7PBl6xhfzVMAGv1uK2; path=/; HttpOnly"},{"key":"Set-Cookie","value":"ss-pid=0PixwjNbLUMFwqV7uhWc; expires=Mon, 19-Oct-2043 08:13:26 GMT; path=/; HttpOnly"},{"key":"Set-Cookie","value":"ss-opt=temp; expires=Mon, 19-Oct-2043 08:13:26 GMT; path=/; HttpOnly"},{"key":"strict-transport-security","value":"max-age=31536000; includeSubdomains"},{"key":"Date","value":"Thu, 19 Oct 2023 08:13:26 GMT"},{"key":"Content-Length","value":"2"}],"cookie":[],"responseTime":null,"body":"OK"}],"_postman_id":"aa83f9d4-f133-4eaf-94e1-fe84333063f4"},{"name":"Bulk import label metadata","id":"aff9baa2-b0d5-434f-b330-d08d78f3c099","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"auth":{"type":"basic","basic":{"basicConfig":[{"key":"username","value":""},{"key":"password","value":""}]},"isInherited":false},"method":"POST","header":[],"body":{"mode":"formdata","formdata":[{"key":"skip","value":"0","description":"

Value for Number of records to skip (integer). Defaults to 0

\n","type":"text"},{"key":"limit","value":"10","description":"

Value for number of records to fetch (integer). Defaults to 100

\n","type":"text"},{"key":"country","value":"all","description":"

Options are \"us\", \"uk\", \"ca\", \"eu\", \"au\", \"all\" (string). Defaults to \"us\"

\n","type":"text"}]},"url":"https://labelae.doctorevidence.com/v2/annotation/label","description":"
    \n

  • Bulk import of all labels in database having annotation data, this will return only label metadata.

    \n
    • \n

  • To be used with skip and limit params.

    \n
    • \n
\n

e.g. To fetch all records, start with skip=0 and limit=100 (100 is max)
and then every subsequent query will skip in multiples of 100
(value of limit)

\n
NOTE: DO NOT USE THIS FOR DAILY MONITORING. THIS IS ONLY TO FETCH DATA FOR INITIAL DATA SET.
\n
All the Params should be passed as raw data in JSON format ( eg. { \"skip\":0, \"limit\":10 } )
\n

Response Data:

\n
    \n

  • current is the total number of active labels retrieved for the given filter criteria.

    \n
    • \n

  • archived is the total number of archived labels that matches the given filter criteria.

    \n
    • \n

  • totalcount is the total number of labels retrieved for the given filter criteria including active and archived.

    \n
    • \n

  • alllabels is the list of label counts region wise.

    \n
    • \n

  • Country is label region.

    \n
    • \n

  • TotalLabels is the total number of annotated labels available for given region.

    \n
    • \n

  • TotalActive is the total number of annotated labels which are active.

    \n
    • \n

  • TotalArchived is the total number of annotated labels which are archived.

    \n
    • \n

  • skip is used to skip the given number of labels from the result, default 0.

    \n
    • \n

  • limit is the number of labels retrieved in the result, default 100.

    \n
    • \n

  • data contains generic name wise list of label details and current MedDRA version.

    \n
    • \n

  • GenericName is the generic name of the label.

    \n
    • \n

  • BaseURL is the base url of the API, that gets the annotation details.

    \n
    • \n

  • MeddraVersion shows the current MedDRA version.

    \n
    • \n

  • Labels contains the list of label details including id(s), ndccode, updated date, country, version and label's annotation details.

    \n
    • \n

  • The Id property uniquely identifies the label.

    \n
      \n

    • For US it is the combination of Country and FileId
      (FileId uniquely identifies the label version).

      \n
      • \n

    • For UK, CA, and EU Id is the combination of Country, ProductId, and Version.

      \n
      • \n

    • e.g. UK19887-2: UK label with productid 19887 and version 2.

      \n
      • \n
    \n
    • \n

  • NDCCode is the label NDC Code, available for US only.

    \n
    • \n

  • UpdatedDate is the date on which the label is imported.

    \n
    • \n

  • LabelSource contains the label id, label version and country of label.

    \n
    • \n

  • LabelTitle displays the title of the label.

    \n
    • \n

  • TradeName shows the BrandName of the label.

    \n
    • \n

  • Manufacturer displays the Manufacturer Name of the label.

    \n
    • \n

  • Country displays the region of the label.

    \n
    • \n

  • ProductId is populated by the SetId for US/AU labels and the ProductId for UK/CA/EU labels.

    \n
    • \n

  • FileId is a unique value for US/AU for each version of the label, while other regions only have ProductId for all the versions of the label. So FileId will be the actual value of the FileId field for the US and AU region, for other regions it will be the combination of ProductId and Version.

    \n
      \n
    • e.g. EUEMEA_H_C_000088-31: productid is EUEMEA_H_C_000088 and version is 31
      (EU label)
      • \n
    \n
    • \n

  • Version shows the latest version of the label.

    \n
    • \n

  • LabelURL shows the label url on parent site.

    \n
    • \n

  • genericNames If the label's generic name is changed, this will show the list of current as well as previous generic names(the label belongs to) or else it will show the current generic name.

    \n
    • \n

  • The response data is sorted by UpdatedDate in ascending order and then sorted by SetId for US/AU labels and by ProductId for UK/CA/EU labels.

    \n
    • \n
\n
NOTE: APPEND _Id_ VALUE AT THE END OF THE _BaseURL_ TO GET THE ANNOTATION DETAILS FOR THE GIVEN LABEL.
\n","urlObject":{"protocol":"https","path":["v2","annotation","label"],"host":["labelae","doctorevidence","com"],"query":[],"variable":[]}},"response":[{"id":"c2842fe6-46b4-4603-881d-4fa1128d1b33","name":"Bulk import label metadata","originalRequest":{"method":"POST","header":[],"body":{"mode":"raw","raw":"{\n \"skip\": 0,\n \"limit\": 10,\n \"country\": \"all\"\n}","options":{"raw":{"language":"json"}}},"url":"https://labelae.doctorevidence.com/v2/annotation/label"},"status":"OK","code":200,"_postman_previewlanguage":"json","header":[{"key":"Content-Encoding","value":"gzip"},{"key":"Content-Type","value":"text/plain; charset=utf-8"},{"key":"Date","value":"Mon, 29 Apr 2024 06:20:24 GMT"},{"key":"Server","value":"Kestrel"},{"key":"Vary","value":"Accept-Encoding"},{"key":"Transfer-Encoding","value":"chunked"}],"cookie":[],"responseTime":null,"body":"{\n \"current\": 45178,\n \"archived\": 0,\n \"totalcount\": 45178,\n \"alllabels\": [\n {\n \"Country\": \"AU\",\n \"TotalLabels\": 7467,\n \"TotalActive\": 7467,\n \"TotalArchived\": 0\n },\n {\n \"Country\": \"UK\",\n \"TotalLabels\": 9769,\n \"TotalActive\": 9769,\n \"TotalArchived\": 0\n },\n {\n \"Country\": \"EU\",\n \"TotalLabels\": 2061,\n \"TotalActive\": 2061,\n \"TotalArchived\": 0\n },\n {\n \"Country\": \"CA\",\n \"TotalLabels\": 11493,\n \"TotalActive\": 11493,\n \"TotalArchived\": 0\n },\n {\n \"Country\": \"US\",\n \"TotalLabels\": 14388,\n \"TotalActive\": 14388,\n \"TotalArchived\": 0\n }\n ],\n \"skip\": 0,\n \"limit\": 10,\n \"BaseURL\": \"https://labelae.doctorevidence.com/V2/annotation/label/\",\n \"MeddraVersion\": \"26.1\",\n \"data\": [\n {\n \"GenericName\": \"california mugwort\",\n \"Labels\": [\n {\n \"Id\": \"USf1334005-3717-4445-b780-d545be0be698\",\n \"NDCCode\": \"36987-3283\",\n \"UpdatedDate\": \"Jun 18, 2012\",\n \"LabelSource\": {\n \"LabelTitle\": \"CALIFORNIA MUGWORT  - artemisia douglasiana pollen injection, solution Nelco Laboratories, Inc.\",\n \"TradeName\": \"California Mugwort\",\n \"Manufacturer\": \"Nelco Laboratories, Inc.\",\n \"Country\": \"us\",\n \"ProductId\": \"02de3b96-7daa-4776-8e2e-c21cf282f091\",\n \"FileId\": \"f1334005-3717-4445-b780-d545be0be698\",\n \"Version\": \"2\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02de3b96-7daa-4776-8e2e-c21cf282f091\",\n \"genericNames\": \"california mugwort\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"cattle epithelium\",\n \"Labels\": [\n {\n \"Id\": \"US8f2b01b8-e712-4107-b824-e1f07faa2a41\",\n \"NDCCode\": \"36987-1003\",\n \"UpdatedDate\": \"Jun 18, 2012\",\n \"LabelSource\": {\n \"LabelTitle\": \"CATTLE EPITHELIUM  - bos taurus skin injection, solution DOG EPITHELIUM  - canis lupus familiaris skin injection, solution CHICKEN FEATHERS  - gallus gallus feather injection, solution DUCK FEATHERS  - anas platyrhynchos feather injection, solution GOOSE FEATHERS  - anser anser feather injection, solution GERBIL EPITHELIUM  - meriones unguiculatus skin injection, solution GOAT EPITHELIUM  - capra hircus skin injection, solution GUINEA PIG EPITHELIUM  - cavia porcellus skin injection, solution HAMSTER EPITHELIUM  - mesocricetus auratus skin injection, solution HOG EPITHELIUM  - sus scrofa skin injection, solution HORSE EPITHELIUM  - equus caballus skin injection, solution MOUSE EPITHELIUM  - mus musculus skin injection, solution RABBIT EPITHELIUM  - oryctolagus cuniculus skin injection, solution RAT EPITHELIUM  - rattus norvegicus skin injection, solution Nelco Laboratories, Inc.\",\n \"TradeName\": \"Cattle Epithelium\",\n \"Manufacturer\": \"Nelco Laboratories, Inc.\",\n \"Country\": \"us\",\n \"ProductId\": \"001dcaf3-5838-4fb0-a4b8-d65ae2eb009e\",\n \"FileId\": \"8f2b01b8-e712-4107-b824-e1f07faa2a41\",\n \"Version\": \"1\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=001dcaf3-5838-4fb0-a4b8-d65ae2eb009e\",\n \"genericNames\": \"cattle epithelium||chicken feathers||dog epithelium||duck feathers||gerbil epithelium||goat epithelium||goose feathers||guinea pig epithelium||hamster epithelium||hog epithelium||horse epithelium||mouse epithelium||rabbit epithelium||rat epithelium\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"timolol\",\n \"Labels\": [\n {\n \"Id\": \"USd3344ae3-17c8-47d4-988b-e872240bffcf\",\n \"NDCCode\": \"68669-525\",\n \"UpdatedDate\": \"Jun 18, 2012\",\n \"LabelSource\": {\n \"LabelTitle\": \"BETIMOL - timolol solution Vistakon Pharmaceuticals LLC\",\n \"TradeName\": \"Betimol\",\n \"Manufacturer\": \"Vistakon Pharmaceuticals LLC\",\n \"Country\": \"us\",\n \"ProductId\": \"00f62dd1-dad2-4892-8a5d-21e5e54509ce\",\n \"FileId\": \"d3344ae3-17c8-47d4-988b-e872240bffcf\",\n \"Version\": \"3\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00f62dd1-dad2-4892-8a5d-21e5e54509ce\",\n \"genericNames\": \"timolol\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"treatment set ts336437\",\n \"Labels\": [\n {\n \"Id\": \"US51d18fca-e7c9-4032-8120-be71ed6e2a7f\",\n \"NDCCode\": \"49288-0786\",\n \"UpdatedDate\": \"Jun 18, 2012\",\n \"LabelSource\": {\n \"LabelTitle\": \"TREATMENT SET TS336437  - alternaria alternata, ambrosia trifida pollen, ambrosia artemisiifolia pollen, ambrosia psilostachya pollen, dermatophagoides pteronyssinus, carya alba pollen, carya illinoinensis pollen, juniperus virginiana pollen, betula nigra pollen, quercus alba pollen, pleospora herbarum, sorghum halepense pollen, kochia scoparia pollen, chenopodium album pollen, iva annua var. annua pollen, amaranthus retroflexus pollen, salsola kali pollen, ustilago nuda hordei, ustilago maydis, ustilago avenae, ustilago tritici, ustilago cynodontis, sporisorium cruentum, poa pratensis pollen, ulmus americana pollen, cynodon dactylon pollen, plantago lanceolata pollen, acer negundo pollen, populus deltoides pollen, fraxinus americana pollen and rumex acetosella pollen injection, solution Antigen Laboratories, Inc.\",\n \"TradeName\": \"Treatment Set TS336437\",\n \"Manufacturer\": \"Antigen Laboratories, Inc.\",\n \"Country\": \"us\",\n \"ProductId\": \"0365a14a-aee4-47c0-952f-3b302e2214a4\",\n \"FileId\": \"51d18fca-e7c9-4032-8120-be71ed6e2a7f\",\n \"Version\": \"1\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0365a14a-aee4-47c0-952f-3b302e2214a4\",\n \"genericNames\": \"treatment set ts336437\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"codfish\",\n \"Labels\": [\n {\n \"Id\": \"US398aea37-e253-4fd4-84ca-ca78367468b5\",\n \"NDCCode\": \"36987-1205\",\n \"UpdatedDate\": \"Jun 18, 2012\",\n \"LabelSource\": {\n \"LabelTitle\": \"CARP  - common carp injection, solution CLAM  - clam injection, solution CODFISH  - codfish injection, solution CRAB  - crab injection, solution FLOUNDER  - flounder injection, solution HADDOCK  - haddock injection, solution HALIBUT  - pacific halibut injection, solution HERRING  - herring injection, solution LOBSTER  - lobster injection, solution MACKEREL  - mackerel injection, solution OYSTER  - oyster injection, solution RED SNAPPER  - red snapper injection, solution SALMON  - atlantic salmon injection, solution SARDINE  - european pilchard injection, solution SCALLOP  - scallop injection, solution SHRIMP  - shrimp injection, solution SWORD FISH  - swordfish injection, solution TROUT  - trout injection, solution TUNA FISH  - tuna injection, solution WHITE FISH  - white fish injection, solution PIKE  - northern pike injection, solution SMELT  - smelt injection, solution Nelco Laboratories, Inc.\",\n \"TradeName\": \"Codfish\",\n \"Manufacturer\": \"Nelco Laboratories, Inc.\",\n \"Country\": \"us\",\n \"ProductId\": \"026f2f1e-71cf-47ab-a24d-66663ff98429\",\n \"FileId\": \"398aea37-e253-4fd4-84ca-ca78367468b5\",\n \"Version\": \"1\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=026f2f1e-71cf-47ab-a24d-66663ff98429\",\n \"genericNames\": \"carp||clam||codfish||crab||flounder||haddock||halibut||herring||lobster||mackerel||oyster||pike||red snapper||salmon||sardine||scallop||shrimp||smelt||sword fish||trout||tuna fish||white fish\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"phenol\",\n \"Labels\": [\n {\n \"Id\": \"US60ce9c8c-5855-42da-91ee-8bfe8edf51ab\",\n \"NDCCode\": \"49288-9933\",\n \"UpdatedDate\": \"Jun 18, 2012\",\n \"LabelSource\": {\n \"LabelTitle\": \"STERILE DILUENT FOR ALLERGENIC EXTRACT  - glycerin and phenol injection, solution STERILE DILUENT FOR ALLERGENIC EXTRACT  - phenol injection, solution STERILE DILUENT FOR ALLERGENIC EXTRACT  - albumin (human) and phenol injection, solution Antigen Laboratories, Inc.\",\n \"TradeName\": \"Sterile Diluent for Allergenic Extract\",\n \"Manufacturer\": \"Antigen Laboratories, Inc.\",\n \"Country\": \"us\",\n \"ProductId\": \"026d3185-aa37-42f8-95a0-7243e0947b7a\",\n \"FileId\": \"60ce9c8c-5855-42da-91ee-8bfe8edf51ab\",\n \"Version\": \"3\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=026d3185-aa37-42f8-95a0-7243e0947b7a\",\n \"genericNames\": \"glycerine||glycerine and phenol||human albumin and phenol||phenol\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"cottonseed\",\n \"Labels\": [\n {\n \"Id\": \"USafc65820-1d95-4bc6-81a6-ef5ca82cbd81\",\n \"NDCCode\": \"49288-0116\",\n \"UpdatedDate\": \"Jun 18, 2012\",\n \"LabelSource\": {\n \"LabelTitle\": \"FLAXSEED  - flax seed injection, solution COFFEE  - arabica coffee bean injection, solution COTTONSEED  - cotton seed injection, solution Antigen Laboratories, Inc.\",\n \"TradeName\": \"Cottonseed\",\n \"Manufacturer\": \"Antigen Laboratories, Inc.\",\n \"Country\": \"us\",\n \"ProductId\": \"040dacaf-4ccf-425a-9b40-586176b7631d\",\n \"FileId\": \"afc65820-1d95-4bc6-81a6-ef5ca82cbd81\",\n \"Version\": \"2\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=040dacaf-4ccf-425a-9b40-586176b7631d\",\n \"genericNames\": \"coffee||cottonseed||flaxseed\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"auranofin\",\n \"Labels\": [\n {\n \"Id\": \"US6008addc-7f8e-45bb-8aec-54dd54a788ac\",\n \"NDCCode\": \"65483-093\",\n \"UpdatedDate\": \"Jun 18, 2012\",\n \"LabelSource\": {\n \"LabelTitle\": \"RIDAURA - auranofin capsule Prometheus Laboratories Inc.\",\n \"TradeName\": \"RIDAURA\",\n \"Manufacturer\": \"PROMETHEUS LABORATORIES INC\",\n \"Country\": \"us\",\n \"ProductId\": \"05c34ddf-a0f7-4267-83f5-d02be3defc37\",\n \"FileId\": \"6008addc-7f8e-45bb-8aec-54dd54a788ac\",\n \"Version\": \"3\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05c34ddf-a0f7-4267-83f5-d02be3defc37\",\n \"genericNames\": \"auranofin\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"cricket\",\n \"Labels\": [\n {\n \"Id\": \"US993fabf7-14f0-4417-9838-d1a609628cb5\",\n \"NDCCode\": \"49288-0160\",\n \"UpdatedDate\": \"Jun 18, 2012\",\n \"LabelSource\": {\n \"LabelTitle\": \"CRICKET  - acheta domesticus injection, solution Antigen Laboratories, Inc.\",\n \"TradeName\": \"Cricket\",\n \"Manufacturer\": \"Antigen Laboratories, Inc.\",\n \"Country\": \"us\",\n \"ProductId\": \"05e233a1-eaaf-4f84-a79c-03f6c59f9dee\",\n \"FileId\": \"993fabf7-14f0-4417-9838-d1a609628cb5\",\n \"Version\": \"1\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05e233a1-eaaf-4f84-a79c-03f6c59f9dee\",\n \"genericNames\": \"cricket\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"nigrospora sphaerica\",\n \"Labels\": [\n {\n \"Id\": \"US333d60d2-2a8c-4a82-922b-490696e55e89\",\n \"NDCCode\": \"36987-2027\",\n \"UpdatedDate\": \"Jun 18, 2012\",\n \"LabelSource\": {\n \"LabelTitle\": \"NIGROSPORA SPHAERICA  - khuskia oryzae injection, solution Nelco Laboratories, Inc.\",\n \"TradeName\": \"Nigrospora sphaerica\",\n \"Manufacturer\": \"Nelco Laboratories, Inc.\",\n \"Country\": \"us\",\n \"ProductId\": \"0668040a-ac04-473c-977f-8c51b7123d46\",\n \"FileId\": \"333d60d2-2a8c-4a82-922b-490696e55e89\",\n \"Version\": \"1\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0668040a-ac04-473c-977f-8c51b7123d46\",\n \"genericNames\": \"nigrospora sphaerica\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n }\n ]\n}"}],"_postman_id":"aff9baa2-b0d5-434f-b330-d08d78f3c099"},{"name":"Get label annotation details","id":"46a1aa60-cd4d-4b7b-8cab-bf2c9ca82c8b","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"auth":{"type":"basic","basic":{"basicConfig":[{"key":"username","value":""},{"key":"password","value":""}]},"isInherited":false},"method":"GET","header":[],"body":{"mode":"raw","raw":""},"url":"https://labelae.doctorevidence.com/V2/annotation/label/:labelid","description":"
    \n
  • Can be used to monitor a specific product label
    • \n
  • Returns label details for a single label using the label id
    • \n
  • The label id can be found as the value of the \"Id\" property for each specific label that is returned using any API endpoint.
    • \n
\n

Response Data:

\n
    \n

  • The Id property uniquely identifies the label.

    \n
      \n

    • For US it is the combination of Country and FileId
      (FileId uniquely identifies the label version).

      \n
      • \n

    • For UK, CA, EU and AU Id is the combination of Country, ProductId, and Version.

      \n
      • \n

    • e.g. UK19887-2: UK label with productid 19887 and version 2.

      \n
      • \n
    \n
    • \n

  • AdverseEventTerms contains the list of adverse terms, their MedDRA code and details about sections in which the term was found.

    \n
    • \n

  • Term is the preferred term found in MedDRA dictionary for the given label.

    \n
    • \n

  • MEDDRACode is a unique eight-digit number assigned to a term by MedDRA.

    \n
    • \n

  • Overdose describes whether the term found in the Overdose section or not.

    \n
    • \n

  • Warnings describes whether the term found in the Warnings section or not.

    \n
    • \n

  • BoxedWarning describes whether the term found in the Boxed Warning section or not.

    \n
    • \n

  • AdverseReactions describes whether the term found in the Adverse Reactions section or not.

    \n
    • \n

  • Contraindications describes whether the term found in the Contraindications section or not.

    \n
    • \n

  • DrugInteractions describes whether the term found in the Drug Interactions section or not.

    \n
    • \n

  • UseInSpecificPopulations contains all the sub-sections of Use In Specific Populations section and describes whether the term found in those sections or not.

    \n
    • \n

  • AnySection describes whether the term found in any of the sub-sections of Use In Specific Populations section or not.

    \n
    • \n

  • Pregnancy describes whether the term found in the Pregnancy section or not.

    \n
    • \n

  • NursingMothers describes whether the term found in the Nursing Mothers section or not.

    \n
    • \n

  • Lactation describes whether the term found in the Lactation section or not.

    \n
    • \n

  • PediatricUse describes whether the term found in the Pediatric Use section or not.

    \n
    • \n

  • GeriatricUse describes whether the term found in the Geriatric Use section or not.

    \n
    • \n

  • Other describes whether the term found in sections other than Overdose, Warnings & Precautions, Boxed Warning, Adverse Drug Reactions, Contraindications, Drug Interactions and Use in specific populations or not.

    \n
    • \n

  • Blacklisted describes whether the term found is blacklisted or not.

    \n
    • \n

  • Annotations contains the list of all VerbatimTerms, Probability and SemanticContext for the given term.

    \n
      \n
    • VerbatimTerm is the raw original term (aka verbatim term).
      • \n
    • Probability is a number between 0 and 1 that represents the confidence of the machine learning model that the term is an Adverse Event (1 being highest and 0 lowest confidence).
      • \n
    • SemanticContext is a snippet of the context from which the verbatim term was extracted, usually the sentence.
      • \n
    \n
    • \n

  • IndicationTerms contains the list of terms found in indication section with their MedDRA code.

    \n
    • \n
\n","urlObject":{"protocol":"https","path":["V2","annotation","label",":labelid"],"host":["labelae","doctorevidence","com"],"query":[],"variable":[{"description":{"content":"

Label Id fetched during bulk imports (string)

\n","type":"text/plain"},"type":"any","value":"USf393776e-af9e-4c52-86a7-b2d7d1a0a002","key":"labelid"}]}},"response":[{"id":"a93365ff-3c67-4ed3-9a96-b9e26bfb26cc","name":"Get label annotation details","originalRequest":{"method":"GET","header":[],"url":{"raw":"https://labelae.doctorevidence.com/V2/annotation/label/:labelid","protocol":"https","host":["labelae","doctorevidence","com"],"path":["V2","annotation","label",":labelid"],"variable":[{"key":"labelid","value":"USf393776e-af9e-4c52-86a7-b2d7d1a0a002","description":"Label Id fetched during imports (string)"}]}},"status":"OK","code":200,"_postman_previewlanguage":"json","header":[{"key":"Cache-Control","value":"private"},{"key":"Content-Type","value":"application/json","description":""},{"key":"Vary","value":"Accept"},{"key":"Server","value":"Microsoft-IIS/8.5"},{"key":"X-StackifyID","value":"V2|b1ba246d-85cd-46db-ac4d-bdbbd5047cdf|C57775|CD6"},{"key":"X-Powered-By","value":"ServiceStack/5.10 NET45 Win32NT/.NET"},{"key":"Access-Control-Allow-Methods","value":"GET, POST, PUT, DELETE, OPTIONS"},{"key":"Access-Control-Allow-Headers","value":"Content-Type, Allow, Authorization, Wait, Accept, X-Requested-With, Put-Default-Position, Put-Before, If-Match, If-None-Match, Content-Range"},{"key":"Access-Control-Allow-Credentials","value":"true"},{"key":"Access-Control-Expose-Headers","value":"Content-Range"},{"key":"X-AspNet-Version","value":"4.0.30319"},{"key":"Set-Cookie","value":"ss-id=HDOYSp316ABiWsmWIhAe; path=/; HttpOnly"},{"key":"Set-Cookie","value":"ss-pid=5M6gGbhz7d7Yma2fijaM; expires=Sat, 21-Mar-2043 11:44:25 GMT; path=/; HttpOnly"},{"key":"Set-Cookie","value":"ss-opt=temp; expires=Sat, 21-Mar-2043 11:44:25 GMT; path=/; HttpOnly"},{"key":"strict-transport-security","value":"max-age=31536000; includeSubdomains"},{"key":"Date","value":"Tue, 21 Mar 2023 11:44:26 GMT"},{"key":"Content-Length","value":"192640"}],"cookie":[],"responseTime":null,"body":"{\n \"Id\": \"USf393776e-af9e-4c52-86a7-b2d7d1a0a002\",\n \"AdverseEventTerms\": [\n {\n \"Term\": \"dependence\",\n \"MEDDRACode\": \"10012335\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"DEPENDENCE\",\n \"Probability\": \"0.0309772193\",\n \"SemanticContext\": \"DRUG ABUSE AND DEPENDENCE Amphetamine sulfate tablets are a Schedule II controlled substance.\"\n }\n ]\n },\n {\n \"Term\": \"dermatosis\",\n \"MEDDRACode\": \"10048768\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"dermatosis\",\n \"Probability\": \"0.6031837463\",\n \"SemanticContext\": \"Manifestations of chronic intoxication with amphetamines include severe dermatosis, marked insomnia, irritability, hyperactivity and personality changes.\"\n }\n ]\n },\n {\n \"Term\": \"disability\",\n \"MEDDRACode\": \"10013050\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"disability\",\n \"Probability\": \"0.3619565964\",\n \"SemanticContext\": \"Tolerance, extreme psychological dependence, and severe social disability have occurred.\"\n }\n ]\n },\n {\n \"Term\": \"drug tolerance\",\n \"MEDDRACode\": \"10052804\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Tolerance\",\n \"Probability\": \"0.0845462978\",\n \"SemanticContext\": \"Tolerance, extreme psychological dependence, and severe social disability have occurred.\"\n }\n ]\n },\n {\n \"Term\": \"irritability\",\n \"MEDDRACode\": \"10022998\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"irritability\",\n \"Probability\": \"0.4632070065\",\n \"SemanticContext\": \"Manifestations of chronic intoxication with amphetamines include severe dermatosis, marked insomnia, irritability, hyperactivity and personality changes.\"\n }\n ]\n },\n {\n \"Term\": \"personality change\",\n \"MEDDRACode\": \"10034719\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"personality changes\",\n \"Probability\": \"0.2237367034\",\n \"SemanticContext\": \"Manifestations of chronic intoxication with amphetamines include severe dermatosis, marked insomnia, irritability, hyperactivity and personality changes.\"\n }\n ]\n },\n {\n \"Term\": \"schizophrenia\",\n \"MEDDRACode\": \"10039626\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"schizophrenia\",\n \"Probability\": \"0.0061277151\",\n \"SemanticContext\": \"The most severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia.\"\n }\n ]\n },\n {\n \"Term\": \"euphoric mood\",\n \"MEDDRACode\": \"10015535\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": true,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"high\",\n \"Probability\": \"0.0011917651\",\n \"SemanticContext\": \"Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG.\"\n },\n {\n \"VerbatimTerm\": \"euphoria\",\n \"Probability\": \"0.9565293789\",\n \"SemanticContext\": \"Central Nervous System Psychotic episodes at recommended doses rare , overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome.\"\n }\n ]\n },\n {\n \"Term\": \"amphetamines\",\n \"MEDDRACode\": \"10063227\",\n \"Overdose\": true,\n \"Warnings\": true,\n \"BoxedWarning\": true,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": true,\n \"UseInSpecificPopulations\": {\n \"AnySection\": true,\n \"Pregnancy\": false,\n \"NursingMothers\": true,\n \"Lactation\": false,\n \"PediatricUse\": true,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Amphetamine\",\n \"Probability\": \"0.014739275\",\n \"SemanticContext\": \"DRUG ABUSE AND DEPENDENCE Amphetamine sulfate tablets are a Schedule II controlled substance.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamines\",\n \"Probability\": \"0.0160472691\",\n \"SemanticContext\": \"Amphetamines have been extensively abused.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0693296194\",\n \"SemanticContext\": \"Manifestations of chronic intoxication with amphetamines include severe dermatosis, marked insomnia, irritability, hyperactivity and personality changes.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0389761627\",\n \"SemanticContext\": \"This is rare with oral amphetamines.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"0.0023454726\",\n \"SemanticContext\": \"There have been isolated reports of cardiomyopathy associated with chronic amphetamine use.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0051548481\",\n \"SemanticContext\": \"Anorexia and weight loss may occur as undesirable effects when amphetamines are used for other than the anorectic effect.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamine\",\n \"Probability\": \"0.001128763\",\n \"SemanticContext\": \"DESCRIPTION Amphetamine sulfate is a sympathomimetic amino of the amphetamine group.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"0.0001532733\",\n \"SemanticContext\": \"DESCRIPTION Amphetamine sulfate is a sympathomimetic amino of the amphetamine group.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"4.72852E-05\",\n \"SemanticContext\": \"Each tablet, for oral administration contains 5 mg or 10 mg of amphetamine sulfate.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamines\",\n \"Probability\": \"0.0639227927\",\n \"SemanticContext\": \"Structural Formula: Chemical Structure CLINICAL PHARMACOLOGY Amphetamines are non-catecholamine, sympathomimetic amines with CNS stimulant activity.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamine\",\n \"Probability\": \"0.0010051429\",\n \"SemanticContext\": \"Amphetamine, as the racemic form, differs from dextroamphetamine in a number of ways.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.040130645\",\n \"SemanticContext\": \"There is neither specific evidence which clearly establishes the mechanism whereby amphetamines produce mental and behavioral effects in children, nor conclusive evidence regarding how those effects relate to the condition of the central nervous system.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0159083307\",\n \"SemanticContext\": \"Drug Interactions \\n\\n Acidifying Agents\\n Gastrointestinal acidifying agents guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc. lower absorption of amphetamines.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"0.0196062028\",\n \"SemanticContext\": \"Urinary acidifying agents ammonium chloride, sodium acid phosphate, etc. increase concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0022209883\",\n \"SemanticContext\": \"Both groups of agents lower blood levels and efficacy of amphetamines.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0186848938\",\n \"SemanticContext\": \"\\n\\n\\n\\n\\n\\n \\n \\n \\n \\n \\n Adrenergic Blockers\\n Adrenergic blockers are inhibited by amphetamines.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0244848728\",\n \"SemanticContext\": \"\\n \\n \\n \\n\\n\\n \\n \\n \\n \\n \\n Alkalinizing Agents\\n Gastrointestinal alkalinizing agents sodium bicarbonate, etc. increase absorption of amphetamines.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"0.0060801506\",\n \"SemanticContext\": \"Urinary alkalinizing agents acetazolamide, some thiazides increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0005933344\",\n \"SemanticContext\": \"Both groups of agents increase blood levels and therefore potentiate the action of amphetamines.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamines\",\n \"Probability\": \"0.0150867105\",\n \"SemanticContext\": \"\\n \\n \\n \\n\\n\\n \\n \\n \\n \\n \\n Antidepressants Tricyclic\\n Amphetamines may enhance the activity of tricyclic or sympathomimetic agents; d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"0.0100767016\",\n \"SemanticContext\": \"\\n \\n \\n \\n\\n\\n \\n \\n \\n \\n \\n Antidepressants Tricyclic\\n Amphetamines may enhance the activity of tricyclic or sympathomimetic agents; d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"0.0005558431\",\n \"SemanticContext\": \"\\n \\n \\n \\n\\n\\n \\n \\n \\n \\n \\n CYP2D6 Inhibitors\\n The concomitant use of amphetamine sulfate tablets and CYP2D6 inhibitors may increase the exposure of amphetamine sulfate tablets compared to the use of the drug alone and increase the risk of serotonin syndrome.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"4.52578E-05\",\n \"SemanticContext\": \"Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome particularly during amphetamine sulfate tablets initiation and after a dosage increase.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"0.0001211347\",\n \"SemanticContext\": \"If serotonin syndrome occurs, discontinue amphetamine sulfate tablets and the CYP2D6 inhibitor \\n see \\n \\n WARNINGS\\n \\n and \\n \\n OVERDOSAGE\\n .\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"0.0029371381\",\n \"SemanticContext\": \"\\n \\n \\n \\n \\n\\n\\n \\n \\n \\n \\n \\n Serotonergic Drugs\\n The concomitant use of amphetamine sulfate tablets and serotonergic drugs increases the risk of serotonin syndrome.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"7.74831E-05\",\n \"SemanticContext\": \"Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during amphetamine sulfate tablets initiation or dosage increase.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"0.0001209293\",\n \"SemanticContext\": \"If serotonin syndrome occurs, discontinue amphetamine sulfate tablets and the concomitant serotonergic drug s \\n see \\n \\n WARNINGS\\n \\n and \\n \\n PRECAUTIONS\\n .\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"0.0182512105\",\n \"SemanticContext\": \"\\n \\n \\n \\n \\n\\n\\n \\n \\n \\n \\n \\n MAO Inhibitors\\n MAOI antidepressants, as well as a metabolic of furazolidone, slow amphetamine metabolism.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0065924525\",\n \"SemanticContext\": \"This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; this can cause headaches and other signs of hypertensive crisis.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamines\",\n \"Probability\": \"0.0462961495\",\n \"SemanticContext\": \"\\n \\n \\n \\n\\n\\n \\n \\n \\n \\n \\n Antihistamines\\n Amphetamines may counteract the sedative effect of antihistamines.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamines\",\n \"Probability\": \"0.024669528\",\n \"SemanticContext\": \"\\n \\n \\n \\n\\n\\n \\n \\n \\n \\n \\n Antihypertensives\\n Amphetamines may antagonize the hypotensive effects of antihypertensives.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"0.0236210823\",\n \"SemanticContext\": \"\\n \\n \\n \\n\\n\\n \\n \\n \\n \\n \\n Chlorpromazine\\n Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamine, and can be used to treat amphetamine poisoning.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamines\",\n \"Probability\": \"0.1714577377\",\n \"SemanticContext\": \"\\n \\n \\n \\n\\n\\n \\n \\n \\n \\n \\n Ethosuximide\\n Amphetamines may delay intestinal absorption of ethosuximide.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0233127177\",\n \"SemanticContext\": \"\\n \\n \\n \\n\\n\\n \\n \\n \\n \\n \\n Haloperidol\\n Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0057734251\",\n \"SemanticContext\": \"\\n \\n \\n \\n\\n\\n \\n \\n \\n \\n \\n Lithium Carbonate\\n The antiobesity and stimulatory effects of amphetamines may be inhibited by lithium carbonate.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamines\",\n \"Probability\": \"0.052485615\",\n \"SemanticContext\": \"\\n \\n \\n \\n\\n\\n \\n \\n \\n \\n \\n Meperidine\\n Amphetamines potentiate the analgesic effect of meperidine.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.064765811\",\n \"SemanticContext\": \"\\n \\n \\n \\n\\n\\n \\n \\n \\n \\n \\n Methenamine Therapy\\n Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamines\",\n \"Probability\": \"0.0316050649\",\n \"SemanticContext\": \"\\n \\n \\n \\n\\n\\n \\n \\n \\n \\n \\n Norepinephrine\\n Amphetamines enhance the adrenergic effect of norepinephrine.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamines\",\n \"Probability\": \"0.1621099114\",\n \"SemanticContext\": \"\\n \\n \\n \\n\\n\\n \\n \\n \\n \\n \\n Phenobarbital\\n Amphetamines may delay intestinal absorption of phenobarbital.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamines\",\n \"Probability\": \"0.0637108386\",\n \"SemanticContext\": \"\\n \\n \\n \\n\\n\\n \\n \\n \\n \\n \\n Phenytoin\\n Amphetamines may delay intestinal absorption of phenytoin; co-administration of phenytoin may produce a synergistic anticonvulsant action.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"0.5230068564\",\n \"SemanticContext\": \"\\n \\n \\n \\n\\n\\n \\n \\n \\n \\n \\n Propoxyphene\\n In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamines\",\n \"Probability\": \"0.0145431757\",\n \"SemanticContext\": \"\\n \\n \\n \\n\\n\\n \\n \\n \\n \\n \\n Veratrum Alkaloids\\n Amphetamines inhibit the hypotensive effect of veratrum alkaloids.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamines\",\n \"Probability\": \"0.0098132193\",\n \"SemanticContext\": \"\\n \\n \\n \\n\\n\\n\\n \\n \\n Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamines\",\n \"Probability\": \"0.0130538344\",\n \"SemanticContext\": \"Amphetamines may interfere with urinary steroid determinations.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"0.0409126282\",\n \"SemanticContext\": \"DOSAGE AND ADMINISTRATION Regardless of indication, amphetamine should be administered at the lowest effective dosage and dosage should be individually adjusted.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"0.0038662851\",\n \"SemanticContext\": \"Narcolepsy seldom occurs in children under 12 years of age; however, when it does, amphetamine sulfate tablets may be used.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamine\",\n \"Probability\": \"0.0855669975\",\n \"SemanticContext\": \"INDICATIONS AND USAGE Amphetamine sulfate tablets are indicated for: Narcolepsy Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures psychological, educational, social for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"8.1294E-06\",\n \"SemanticContext\": \"The limited usefulness of amphetamines see CLINICAL PHARMACOLOGY should be weighed against possible risks inherent in use of the drug, such as those described below.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamines\",\n \"Probability\": \"0.0003992319\",\n \"SemanticContext\": \"Information for Patients Amphetamines may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or vehicle; the patient should therefore be cautioned accordingly.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0040230751\",\n \"SemanticContext\": \"OVERDOSAGE Individual patient response to amphetamines varies widely.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.2555670142\",\n \"SemanticContext\": \"Symptoms Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rhabdomyolysis, rapid respiration, hyperpyrexia, confusion, assaultiveness, hallucinations, panic states.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"4.25457E-05\",\n \"SemanticContext\": \"Acidification of the urine increases amphetamine excretion.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"3.07148E-05\",\n \"SemanticContext\": \"If acute, severe hypertension complicates amphetamine overdosage, administration of intravenous phentolamine has been suggested.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0009275973\",\n \"SemanticContext\": \"Chlorpromazine antagonizes the central stimulant effects of amphetamines and can be used to treat amphetamine intoxication.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"0.0002489388\",\n \"SemanticContext\": \"Chlorpromazine antagonizes the central stimulant effects of amphetamines and can be used to treat amphetamine intoxication.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"0.0526750982\",\n \"SemanticContext\": \"In a pooled analysis of multiple short-term, placebo-controlled studies, such symptoms occurred in about 0.1% 4 patients with events out of 3482 exposed to methylphenidate or amphetamine for several weeks at usual doses of stimulant-treated patients compared to 0 in placebo-treated patients.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0001533031\",\n \"SemanticContext\": \"Published data are inadequate to determine whether chronic use of amphetamines may cause a similar suppression of growth, however, it is anticipated that they likely have this effect as well.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"0.0059112906\",\n \"SemanticContext\": \"Peripheral Vasculopathy, Including Raynaud's Phenomenon Stimulants, including amphetamine sulfate tablets, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0096366107\",\n \"SemanticContext\": \"Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors MAOIs , selective serotonin reuptake inhibitors SSRIs , serotonin norepinephrine reuptake inhibitors SNRIs , triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort see DRUG INTERACTIONS .\"\n },\n {\n \"VerbatimTerm\": \"Amphetamines\",\n \"Probability\": \"0.0038147569\",\n \"SemanticContext\": \"Amphetamines and amphetamine derivatives are known to be metabolized, to some degree, by cytochrome P450 2D6 CYP2D6 and display minor inhibition of CYP2D6 metabolism see CLINICAL PHARMACOLOGY .\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"0.0018995106\",\n \"SemanticContext\": \"Amphetamines and amphetamine derivatives are known to be metabolized, to some degree, by cytochrome P450 2D6 CYP2D6 and display minor inhibition of CYP2D6 metabolism see CLINICAL PHARMACOLOGY .\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"0.0135577619\",\n \"SemanticContext\": \"The potential for a pharmacokinetic interaction exists with the co-administration of CYP2D6 inhibitors which may increase the risk with increased exposure to amphetamine sulfate tablets.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"9.41276E-05\",\n \"SemanticContext\": \"Concomitant use of amphetamine sulfate tablets with MAOI drugs is contraindicated see CONTRAINDICATIONS .\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"1.49045E-05\",\n \"SemanticContext\": \"Discontinue treatment with amphetamine sulfate tablets and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"5.4398E-06\",\n \"SemanticContext\": \"If concomitant use of amphetamine sulfate tablets with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate amphetamine sulfate tablets with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"1.44551E-05\",\n \"SemanticContext\": \"PRECAUTIONS General Caution is to be exercised in prescribing amphetamines for patients with even mild hypertension.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"2.27677E-05\",\n \"SemanticContext\": \"\\n <text>\\n <paragraph>Circulation problems in fingers and toes [Peripheral vasculopathy, including Raynaud's phenomenon]</paragraph>\\n <list?listType=\\\"unordered\\\"?styleCode=\\\"Disk\\\">\\n <item>Instruct patients beginning treatment with amphetamine sulfate tablets about the risk of peripheral vasculopathy, including Raynaud's phenomenon, and associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change color from pale, to blue, to red.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"5.64523E-05\",\n \"SemanticContext\": \"</item>\\n <item>\\n <content?styleCode=\\\"bold\\\">Instruct patients to call their physician immediately with any signs of unexplained wounds appearing on fingers or toes while taking amphetamine sulfate tablets.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0166814327\",\n \"SemanticContext\": \"\\n </item>\\n </list>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n</section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_98f61d75-3c2e-429d-9225-8c171ea8fcb6\\\">\\n <id?root=\\\"c0b0a338-b468-47e1-81f5-733cab50e6b6\\\"?/>\\n <code?code=\\\"34073-7\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"DRUG?INTERACTIONS?SECTION\\\"?/>\\n <title>Drug Interactions \\n <text>\\n <paragraph>Acidifying Agents</paragraph>\\n <paragraph>Gastrointestinal acidifying agents guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc. lower absorption of amphetamines.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamines\",\n \"Probability\": \"0.0098132193\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n</section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_3e0f5ebc-7163-495b-9c6f-1034630fb209\\\">\\n <id?root=\\\"ab9fac15-a26a-4e92-b657-3ae851c4208c\\\"?/>\\n <code?code=\\\"34074-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"DRUG?&?OR?LABORATORY?TEST?INTERACTIONS?SECTION\\\"?/>\\n <title>Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels.\"\n },\n {\n \"VerbatimTerm\": \"amphetamine\",\n \"Probability\": \"0.00123927\",\n \"SemanticContext\": \"Carcinogenesis/Mutagenesis Mutagenicity studies and long term studies in animals to determine the carcinogenic potential of amphetamine sulfate have not been performed.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamine\",\n \"Probability\": \"0.0039381385\",\n \"SemanticContext\": \"Amphetamine sulfate tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0084707141\",\n \"SemanticContext\": \"\\n </paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n</section>\\n</component>\\n</section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_7ac38a51-b94e-4f52-9d33-e82f66656f34\\\">\\n <id?root=\\\"85889fa7-56ab-4d35-bb9b-2d661b5b280a\\\"?/>\\n <code?code=\\\"34078-6\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"NONTERATOGENIC?EFFECTS?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Nonteratogenic Effects</paragraph>\\n <paragraph>Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamines\",\n \"Probability\": \"0.0023192763\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n</component>\\n</section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_265f80b1-f6f8-44fc-9b11-f9f4c78aaf2d\\\">\\n <id?root=\\\"fbbfb7d9-be33-47d1-a01f-3d93dcc4d1ea\\\"?/>\\n <code?code=\\\"34080-2\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"NURSING?MOTHERS?SECTION\\\"?/>\\n <title>Nursing Mothers Amphetamines are excreted in human milk.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0011845231\",\n \"SemanticContext\": \"Mothers taking amphetamines should be advised to refrain from nursing.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"1.26965E-05\",\n \"SemanticContext\": \"Pediatric Use Long-term effects of amphetamines in children have not been well established.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamines\",\n \"Probability\": \"0.0094379187\",\n \"SemanticContext\": \"Amphetamines are not recommended for use as anorectic agents in children under 12 years of age, or in children under 3 years of age with Attention Deficit Disorder with Hyperactivity described under INDICATIONS AND USAGE.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0436177552\",\n \"SemanticContext\": \"Clinical experience suggests that in psychotic children, administration of amphetamines may exacerbate symptoms of behavior disturbance and thought disorder.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamines\",\n \"Probability\": \"0.1891292334\",\n \"SemanticContext\": \"Amphetamines have been reported to exacerbate motor and phonic tics and Tourette's syndrome.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"3.86938E-05\",\n \"SemanticContext\": \"Data is inadequate to determine whether chronic administration of amphetamines may be associated with growth inhibition; therefore growth should be monitored during treatment.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0001038334\",\n \"SemanticContext\": \"The decision to prescribe amphetamines should depend on the physician's assessment of the chronicity and severity of the child's symptoms and their appropriateness for his/her age.\"\n },\n {\n \"VerbatimTerm\": \"amphetamines\",\n \"Probability\": \"0.0014252067\",\n \"SemanticContext\": \"When these symptoms are associated with acute stress reactions, treatment with amphetamines is usually not indicated.\"\n },\n {\n \"VerbatimTerm\": \"Amphetamines\",\n \"Probability\": \"0.0002590716\",\n \"SemanticContext\": \"Nursing Mothers Amphetamines are excreted in human milk.\"\n }\n ]\n },\n {\n \"Term\": \"insomnia\",\n \"MEDDRACode\": \"10022437\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"insomnia\",\n \"Probability\": \"0.4686983824\",\n \"SemanticContext\": \"Manifestations of chronic intoxication with amphetamines include severe dermatosis, marked insomnia, irritability, hyperactivity and personality changes.\"\n },\n {\n \"VerbatimTerm\": \"insomnia\",\n \"Probability\": \"0.9976198673\",\n \"SemanticContext\": \"Central Nervous System Psychotic episodes at recommended doses rare , overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome.\"\n },\n {\n \"VerbatimTerm\": \"insomnia\",\n \"Probability\": \"0.0004678071\",\n \"SemanticContext\": \"Late evening doses should be avoided because of resulting insomnia.\"\n },\n {\n \"VerbatimTerm\": \"insomnia\",\n \"Probability\": \"0.0144157112\",\n \"SemanticContext\": \"If bothersome adverse reactions appear e.g., insomnia or anorexia dosage should be reduced.\"\n }\n ]\n },\n {\n \"Term\": \"psychotic disorder\",\n \"MEDDRACode\": \"10061920\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": true,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": true,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"psychosis\",\n \"Probability\": \"0.126097858\",\n \"SemanticContext\": \"The most severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia.\"\n },\n {\n \"VerbatimTerm\": \"Psychotic episodes\",\n \"Probability\": \"0.4993687272\",\n \"SemanticContext\": \"Central Nervous System Psychotic episodes at recommended doses rare , overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome.\"\n },\n {\n \"VerbatimTerm\": \"psychotic disorder\",\n \"Probability\": \"0.0738732219\",\n \"SemanticContext\": \"\\n </paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n</section>\\n</component>\\n</section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_f28bfe4d-6b1f-407e-8d65-44f84f42ab56\\\">\\n <id?root=\\\"51243722-0c1b-4804-87e7-742294dd22fd\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title>Psychiatric Adverse Events \\n <text>\\n <paragraph>Pre-Existing Psychosis</paragraph>\\n <paragraph>Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.\"\n },\n {\n \"VerbatimTerm\": \"Psychosis\",\n \"Probability\": \"0.0026338696\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n</section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_f28bfe4d-6b1f-407e-8d65-44f84f42ab56\\\">\\n <id?root=\\\"51243722-0c1b-4804-87e7-742294dd22fd\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title>Psychiatric Adverse Events \\n <text>\\n <paragraph>Pre-Existing Psychosis</paragraph>\\n <paragraph>Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.\"\n },\n {\n \"VerbatimTerm\": \"Psychotic\",\n \"Probability\": \"0.0459209085\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_c5a7020c-ca8a-4389-bdf6-1d6ce18b63d0\\\">\\n <id?root=\\\"62edd24b-b963-41b8-ab35-510f34b821a5\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Emergence of New Psychotic or Manic Symptoms</paragraph>\\n <paragraph>Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania can be caused by stimulants at usual doses.\"\n },\n {\n \"VerbatimTerm\": \"psychotic\",\n \"Probability\": \"0.043692708\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_c5a7020c-ca8a-4389-bdf6-1d6ce18b63d0\\\">\\n <id?root=\\\"62edd24b-b963-41b8-ab35-510f34b821a5\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Emergence of New Psychotic or Manic Symptoms</paragraph>\\n <paragraph>Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania can be caused by stimulants at usual doses.\"\n },\n {\n \"VerbatimTerm\": \"psychotic\",\n \"Probability\": \"0.0068537593\",\n \"SemanticContext\": \"Clinical experience suggests that in psychotic children, administration of amphetamines may exacerbate symptoms of behavior disturbance and thought disorder.\"\n }\n ]\n },\n {\n \"Term\": \"drug dependence\",\n \"MEDDRACode\": \"10013663\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": true,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"psychological dependence\",\n \"Probability\": \"0.0943036377\",\n \"SemanticContext\": \"Tolerance, extreme psychological dependence, and severe social disability have occurred.\"\n }\n ]\n },\n {\n \"Term\": \"substance abuse\",\n \"MEDDRACode\": \"10066169\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": true,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"abused\",\n \"Probability\": \"0.0022118688\",\n \"SemanticContext\": \"Amphetamines have been extensively abused.\"\n }\n ]\n },\n {\n \"Term\": \"drug abuse\",\n \"MEDDRACode\": \"10013654\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": true,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"DRUG ABUSE\",\n \"Probability\": \"0.0014652908\",\n \"SemanticContext\": \"DRUG ABUSE AND DEPENDENCE Amphetamine sulfate tablets are a Schedule II controlled substance.\"\n },\n {\n \"VerbatimTerm\": \"drug abuse\",\n \"Probability\": \"0.0001458526\",\n \"SemanticContext\": \"Patients with a history of drug abuse.\"\n }\n ]\n },\n {\n \"Term\": \"psychomotor hyperactivity\",\n \"MEDDRACode\": \"10037211\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": true,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": true,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"hyperactivity\",\n \"Probability\": \"0.6854095459\",\n \"SemanticContext\": \"Manifestations of chronic intoxication with amphetamines include severe dermatosis, marked insomnia, irritability, hyperactivity and personality changes.\"\n },\n {\n \"VerbatimTerm\": \"Hyperactivity\",\n \"Probability\": \"0.0008975267\",\n \"SemanticContext\": \"Attention Deficit Disorder with Hyperactivity Not recommended for children under 3 years of age.\"\n },\n {\n \"VerbatimTerm\": \"Hyperactivity\",\n \"Probability\": \"0.213891685\",\n \"SemanticContext\": \"INDICATIONS AND USAGE Amphetamine sulfate tablets are indicated for: Narcolepsy Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures psychological, educational, social for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.\"\n },\n {\n \"VerbatimTerm\": \"hyperactivity\",\n \"Probability\": \"0.8059383631\",\n \"SemanticContext\": \"INDICATIONS AND USAGE Amphetamine sulfate tablets are indicated for: Narcolepsy Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures psychological, educational, social for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.\"\n },\n {\n \"VerbatimTerm\": \"Hyperactivity\",\n \"Probability\": \"0.0008568764\",\n \"SemanticContext\": \"Amphetamines are not recommended for use as anorectic agents in children under 12 years of age, or in children under 3 years of age with Attention Deficit Disorder with Hyperactivity described under INDICATIONS AND USAGE.\"\n },\n {\n \"VerbatimTerm\": \"Hyperactivity\",\n \"Probability\": \"0.0095364153\",\n \"SemanticContext\": \"Drug treatment is not indicated in all cases of Attention Deficit Disorder with Hyperactivity and should be considered only in light of the complete history and evaluation of the child.\"\n }\n ]\n },\n {\n \"Term\": \"poisoning\",\n \"MEDDRACode\": \"10061355\",\n \"Overdose\": true,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": true,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"intoxication\",\n \"Probability\": \"0.0867268443\",\n \"SemanticContext\": \"Manifestations of chronic intoxication with amphetamines include severe dermatosis, marked insomnia, irritability, hyperactivity and personality changes.\"\n },\n {\n \"VerbatimTerm\": \"intoxication\",\n \"Probability\": \"0.2321059704\",\n \"SemanticContext\": \"The most severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia.\"\n },\n {\n \"VerbatimTerm\": \"poisoning\",\n \"Probability\": \"0.0028888583\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_23311580-d20a-493e-91c1-35257ab2d9f0\\\">\\n <id?root=\\\"9932814a-a838-4aad-ad63-1b8d3393d678\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Chlorpromazine</paragraph>\\n <paragraph>Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamine, and can be used to treat amphetamine poisoning.\"\n },\n {\n \"VerbatimTerm\": \"poisoning\",\n \"Probability\": \"0.9029369354\",\n \"SemanticContext\": \"Fatal poisoning is usually preceded by convulsions and coma.\"\n },\n {\n \"VerbatimTerm\": \"intoxication\",\n \"Probability\": \"0.0006680489\",\n \"SemanticContext\": \"Chlorpromazine antagonizes the central stimulant effects of amphetamines and can be used to treat amphetamine intoxication.\"\n }\n ]\n },\n {\n \"Term\": \"depression\",\n \"MEDDRACode\": \"10012378\",\n \"Overdose\": true,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"mental depression\",\n \"Probability\": \"0.0086975098\",\n \"SemanticContext\": \"Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG.\"\n },\n {\n \"VerbatimTerm\": \"depression\",\n \"Probability\": \"0.1527172923\",\n \"SemanticContext\": \"Fatigue and depression usually follow the central stimulation.\"\n },\n {\n \"VerbatimTerm\": \"depression\",\n \"Probability\": \"0.1035991013\",\n \"SemanticContext\": \"Prior to initiating treatment with a stimulant, patients with comorbid depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.\"\n }\n ]\n },\n {\n \"Term\": \"fatigue\",\n \"MEDDRACode\": \"10016256\",\n \"Overdose\": true,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"extreme fatigue\",\n \"Probability\": \"0.1219728291\",\n \"SemanticContext\": \"Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG.\"\n },\n {\n \"VerbatimTerm\": \"Fatigue\",\n \"Probability\": \"0.8171851635\",\n \"SemanticContext\": \"Fatigue and depression usually follow the central stimulation.\"\n },\n {\n \"VerbatimTerm\": \"lassitude\",\n \"Probability\": \"0.7751655579\",\n \"SemanticContext\": \"Also, these infants may experience symptoms of withdrawal as demonstrated by dysphoria, including agitation, and significant lassitude.\"\n }\n ]\n },\n {\n \"Term\": \"electroencephalogram\",\n \"MEDDRACode\": \"10014407\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"EEG\",\n \"Probability\": \"0.0014368296\",\n \"SemanticContext\": \"Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG.\"\n },\n {\n \"VerbatimTerm\": \"EEG\",\n \"Probability\": \"0.0008171797\",\n \"SemanticContext\": \"Seizures There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures.\"\n }\n ]\n },\n {\n \"Term\": \"constipation\",\n \"MEDDRACode\": \"10010774\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"constipation\",\n \"Probability\": \"0.9966984987\",\n \"SemanticContext\": \"Gastrointestinal Dryness of the mouth, unpleasant taste, diarrhea, constipation, intestinal ischemia and other gastrointestinal disturbances.\"\n }\n ]\n },\n {\n \"Term\": \"dyskinesia\",\n \"MEDDRACode\": \"10013916\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"dyskinesia\",\n \"Probability\": \"0.9987421036\",\n \"SemanticContext\": \"Central Nervous System Psychotic episodes at recommended doses rare , overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome.\"\n }\n ]\n },\n {\n \"Term\": \"erectile dysfunction\",\n \"MEDDRACode\": \"10061461\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Impotence\",\n \"Probability\": \"0.6297879815\",\n \"SemanticContext\": \"Allergic Urticaria Endocrine Impotence, changes in libido, and frequent or prolonged erections.\"\n }\n ]\n },\n {\n \"Term\": \"erection increased\",\n \"MEDDRACode\": \"10015120\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"prolonged erections\",\n \"Probability\": \"0.9931793213\",\n \"SemanticContext\": \"Allergic Urticaria Endocrine Impotence, changes in libido, and frequent or prolonged erections.\"\n }\n ]\n },\n {\n \"Term\": \"gastrointestinal disorder\",\n \"MEDDRACode\": \"10017944\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"gastrointestinal disturbances\",\n \"Probability\": \"0.8119831681\",\n \"SemanticContext\": \"Gastrointestinal Dryness of the mouth, unpleasant taste, diarrhea, constipation, intestinal ischemia and other gastrointestinal disturbances.\"\n }\n ]\n },\n {\n \"Term\": \"intestinal ischaemia\",\n \"MEDDRACode\": \"10022680\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"intestinal ischemia\",\n \"Probability\": \"0.986882329\",\n \"SemanticContext\": \"Gastrointestinal Dryness of the mouth, unpleasant taste, diarrhea, constipation, intestinal ischemia and other gastrointestinal disturbances.\"\n }\n ]\n },\n {\n \"Term\": \"palpitations\",\n \"MEDDRACode\": \"10033557\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Palpitations\",\n \"Probability\": \"0.9687367678\",\n \"SemanticContext\": \"ADVERSE REACTIONS Cardiovascular Palpitations, tachycardia, elevation of blood pressure.\"\n }\n ]\n },\n {\n \"Term\": \"urticaria\",\n \"MEDDRACode\": \"10046735\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Allergic Urticaria\",\n \"Probability\": \"0.9743586183\",\n \"SemanticContext\": \"Allergic Urticaria Endocrine Impotence, changes in libido, and frequent or prolonged erections.\"\n }\n ]\n },\n {\n \"Term\": \"weight decreased\",\n \"MEDDRACode\": \"10047895\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"weight loss\",\n \"Probability\": \"0.6615606546\",\n \"SemanticContext\": \"Anorexia and weight loss may occur as undesirable effects when amphetamines are used for other than the anorectic effect.\"\n },\n {\n \"VerbatimTerm\": \"weight loss of\",\n \"Probability\": \"0.8840100169\",\n \"SemanticContext\": \"The magnitude of increased weight loss of drug-treated patients over placebo-treated patients is only a fraction of a pound a week.\"\n },\n {\n \"VerbatimTerm\": \"of weight loss\",\n \"Probability\": \"0.9313257933\",\n \"SemanticContext\": \"The rate of weight loss is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks.\"\n },\n {\n \"VerbatimTerm\": \"weight loss\",\n \"Probability\": \"0.0997694135\",\n \"SemanticContext\": \"The origins of the increased weight loss due to the various possible drug effects are not established.\"\n },\n {\n \"VerbatimTerm\": \"of weight loss\",\n \"Probability\": \"0.1058771014\",\n \"SemanticContext\": \"The amount of weight loss associated with the use of an \\\"anorectic\\\" drug varies from trial to trial, and the increased weight loss appears to be related in part to variables other than the drug prescribed, such as the physician-investigator, the population treated, and the diet prescribed.\"\n },\n {\n \"VerbatimTerm\": \"weight loss\",\n \"Probability\": \"0.1126325428\",\n \"SemanticContext\": \"The amount of weight loss associated with the use of an \\\"anorectic\\\" drug varies from trial to trial, and the increased weight loss appears to be related in part to variables other than the drug prescribed, such as the physician-investigator, the population treated, and the diet prescribed.\"\n },\n {\n \"VerbatimTerm\": \"weight loss\",\n \"Probability\": \"0.0949011743\",\n \"SemanticContext\": \"Studies do not permit conclusions as to the relative importance of the drug and nondrug factors on weight loss.\"\n },\n {\n \"VerbatimTerm\": \"weight loss\",\n \"Probability\": \"0.0072132051\",\n \"SemanticContext\": \"The natural history of obesity is measured in years, whereas the studies cited are restricted to few weeks duration; thus, the total impact of drug-induced weight loss over that of diet alone must be considered clinically limited.\"\n }\n ]\n },\n {\n \"Term\": \"decreased appetite\",\n \"MEDDRACode\": \"10061428\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": true,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": true,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Anorexia\",\n \"Probability\": \"0.4887568951\",\n \"SemanticContext\": \"Anorexia and weight loss may occur as undesirable effects when amphetamines are used for other than the anorectic effect.\"\n },\n {\n \"VerbatimTerm\": \"anorectic\",\n \"Probability\": \"0.4167717099\",\n \"SemanticContext\": \"Anorexia and weight loss may occur as undesirable effects when amphetamines are used for other than the anorectic effect.\"\n },\n {\n \"VerbatimTerm\": \"anorectics\",\n \"Probability\": \"0.0796794891\",\n \"SemanticContext\": \"Drugs in this class used in obesity are commonly known as \\\"anorectics\\\" or \\\"anorexigenics.\\\"\"\n },\n {\n \"VerbatimTerm\": \"appetite suppression\",\n \"Probability\": \"0.3997294009\",\n \"SemanticContext\": \"It has not been established, however, that the action of such drugs in treating obesity is primarily one of appetite suppression.\"\n },\n {\n \"VerbatimTerm\": \"anorectic\",\n \"Probability\": \"0.0001225976\",\n \"SemanticContext\": \"Adult obese subjects instructed in dietary management and treated with \\\"anorectic\\\" drugs lose more weight on the average than these treated with placebo and diet, as determined in relatively short-term clinical trials.\"\n },\n {\n \"VerbatimTerm\": \"anorectic\",\n \"Probability\": \"0.0675163567\",\n \"SemanticContext\": \"The amount of weight loss associated with the use of an \\\"anorectic\\\" drug varies from trial to trial, and the increased weight loss appears to be related in part to variables other than the drug prescribed, such as the physician-investigator, the population treated, and the diet prescribed.\"\n },\n {\n \"VerbatimTerm\": \"anorexia\",\n \"Probability\": \"0.0137174428\",\n \"SemanticContext\": \"If bothersome adverse reactions appear e.g., insomnia or anorexia dosage should be reduced.\"\n },\n {\n \"VerbatimTerm\": \"anorectic\",\n \"Probability\": \"0.000998944\",\n \"SemanticContext\": \"Amphetamines are not recommended for use as anorectic agents in children under 12 years of age, or in children under 3 years of age with Attention Deficit Disorder with Hyperactivity described under INDICATIONS AND USAGE.\"\n }\n ]\n },\n {\n \"Term\": \"nervousness\",\n \"MEDDRACode\": \"10029216\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Nervous\",\n \"Probability\": \"0.0546081662\",\n \"SemanticContext\": \"Central Nervous System Psychotic episodes at recommended doses rare , overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome.\"\n },\n {\n \"VerbatimTerm\": \"nervous\",\n \"Probability\": \"0.0520266294\",\n \"SemanticContext\": \"There is neither specific evidence which clearly establishes the mechanism whereby amphetamines produce mental and behavioral effects in children, nor conclusive evidence regarding how those effects relate to the condition of the central nervous system.\"\n },\n {\n \"VerbatimTerm\": \"nervous\",\n \"Probability\": \"0.0005308092\",\n \"SemanticContext\": \"Other central nervous system actions or metabolic effects, may be involved, for example.\"\n },\n {\n \"VerbatimTerm\": \"nervous\",\n \"Probability\": \"0.0017792284\",\n \"SemanticContext\": \"Nonlocalizing soft neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or not be warranted.\"\n }\n ]\n },\n {\n \"Term\": \"headache\",\n \"MEDDRACode\": \"10019211\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": true,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"headache\",\n \"Probability\": \"0.9942373633\",\n \"SemanticContext\": \"Central Nervous System Psychotic episodes at recommended doses rare , overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome.\"\n },\n {\n \"VerbatimTerm\": \"headaches\",\n \"Probability\": \"0.1153029203\",\n \"SemanticContext\": \"This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; this can cause headaches and other signs of hypertensive crisis.\"\n }\n ]\n },\n {\n \"Term\": \"restlessness\",\n \"MEDDRACode\": \"10038743\",\n \"Overdose\": true,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"restlessness\",\n \"Probability\": \"0.9934930801\",\n \"SemanticContext\": \"Central Nervous System Psychotic episodes at recommended doses rare , overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome.\"\n },\n {\n \"VerbatimTerm\": \"restlessness\",\n \"Probability\": \"0.4358330071\",\n \"SemanticContext\": \"Symptoms Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rhabdomyolysis, rapid respiration, hyperpyrexia, confusion, assaultiveness, hallucinations, panic states.\"\n }\n ]\n },\n {\n \"Term\": \"rhabdomyolysis\",\n \"MEDDRACode\": \"10039020\",\n \"Overdose\": true,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Rhabdomyolysis\",\n \"Probability\": \"0.497628957\",\n \"SemanticContext\": \"Musculoskeletal Rhabdomyolysis\"\n },\n {\n \"VerbatimTerm\": \"rhabdomyolysis\",\n \"Probability\": \"0.9575566053\",\n \"SemanticContext\": \"Symptoms Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rhabdomyolysis, rapid respiration, hyperpyrexia, confusion, assaultiveness, hallucinations, panic states.\"\n }\n ]\n },\n {\n \"Term\": \"diarrhoea\",\n \"MEDDRACode\": \"10012735\",\n \"Overdose\": true,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"diarrhea\",\n \"Probability\": \"0.9933217764\",\n \"SemanticContext\": \"Gastrointestinal Dryness of the mouth, unpleasant taste, diarrhea, constipation, intestinal ischemia and other gastrointestinal disturbances.\"\n },\n {\n \"VerbatimTerm\": \"diarrhea\",\n \"Probability\": \"0.9994111657\",\n \"SemanticContext\": \"Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps.\"\n },\n {\n \"VerbatimTerm\": \"diarrhea\",\n \"Probability\": \"0.968662858\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n }\n ]\n },\n {\n \"Term\": \"tremor\",\n \"MEDDRACode\": \"10044565\",\n \"Overdose\": true,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"tremor\",\n \"Probability\": \"0.9951730967\",\n \"SemanticContext\": \"Central Nervous System Psychotic episodes at recommended doses rare , overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome.\"\n },\n {\n \"VerbatimTerm\": \"tremor\",\n \"Probability\": \"0.7453406453\",\n \"SemanticContext\": \"Symptoms Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rhabdomyolysis, rapid respiration, hyperpyrexia, confusion, assaultiveness, hallucinations, panic states.\"\n },\n {\n \"VerbatimTerm\": \"tremor\",\n \"Probability\": \"0.9942228794\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n }\n ]\n },\n {\n \"Term\": \"blood pressure measurement\",\n \"MEDDRACode\": \"10076581\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"blood pressure\",\n \"Probability\": \"0.0518221855\",\n \"SemanticContext\": \"ADVERSE REACTIONS Cardiovascular Palpitations, tachycardia, elevation of blood pressure.\"\n },\n {\n \"VerbatimTerm\": \"blood pressure\",\n \"Probability\": \"0.0008813739\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n</section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_a8c33687-9be4-4bbe-b513-5ea06f35844b\\\">\\n <id?root=\\\"ae542c3e-c674-44f7-be43-483a5ae2fe56\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Hypertension and Other Cardiovascular Conditions</paragraph>\\n <paragraph>Stimulant medications cause a modest increase in average blood pressure about 2 to 4 mmHg and average heart rate about 3 to 6 bpm , and individuals may have larger increases.\"\n },\n {\n \"VerbatimTerm\": \"blood pressure\",\n \"Probability\": \"0.0002478957\",\n \"SemanticContext\": \"While the mean changes alone would not be expected to have short-term consequences, all patients should be monitored for larger changes in heart rate and blood pressure.\"\n }\n ]\n },\n {\n \"Term\": \"cardiomyopathy\",\n \"MEDDRACode\": \"10007636\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"cardiomyopathy\",\n \"Probability\": \"0.4876176417\",\n \"SemanticContext\": \"There have been isolated reports of cardiomyopathy associated with chronic amphetamine use.\"\n },\n {\n \"VerbatimTerm\": \"cardiomyopathy\",\n \"Probability\": \"0.0016779006\",\n \"SemanticContext\": \"Although some serious heart problems alone carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug \\n <content?styleCode=\\\"italics\\\">see </content>\\n <content?styleCode=\\\"bold\\\">\\n <linkHtml?href=\\\"#LINK_2f759a45-d082-4553-9ba5-71ca27a70c92\\\">CONTRAINDICATIONS</linkHtml>\\n </content> .\"\n },\n {\n \"VerbatimTerm\": \"cardiomyopathy\",\n \"Probability\": \"0.0073139071\",\n \"SemanticContext\": \"Although the role of stimulants in these adult cases is also unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems.\"\n }\n ]\n },\n {\n \"Term\": \"dizziness\",\n \"MEDDRACode\": \"10013573\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"dizziness\",\n \"Probability\": \"0.9994892478\",\n \"SemanticContext\": \"Central Nervous System Psychotic episodes at recommended doses rare , overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome.\"\n },\n {\n \"VerbatimTerm\": \"dizziness\",\n \"Probability\": \"0.8335459232\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n }\n ]\n },\n {\n \"Term\": \"dysphoria\",\n \"MEDDRACode\": \"10013954\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"dysphoria\",\n \"Probability\": \"0.9955378771\",\n \"SemanticContext\": \"Central Nervous System Psychotic episodes at recommended doses rare , overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome.\"\n },\n {\n \"VerbatimTerm\": \"dysphoria\",\n \"Probability\": \"0.8919098973\",\n \"SemanticContext\": \"Also, these infants may experience symptoms of withdrawal as demonstrated by dysphoria, including agitation, and significant lassitude.\"\n }\n ]\n },\n {\n \"Term\": \"tachycardia\",\n \"MEDDRACode\": \"10043071\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"tachycardia\",\n \"Probability\": \"0.9971472025\",\n \"SemanticContext\": \"ADVERSE REACTIONS Cardiovascular Palpitations, tachycardia, elevation of blood pressure.\"\n },\n {\n \"VerbatimTerm\": \"tachycardia\",\n \"Probability\": \"0.9948868752\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n }\n ]\n },\n {\n \"Term\": \"tic\",\n \"MEDDRACode\": \"10043833\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": true,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": true,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"tics\",\n \"Probability\": \"0.6931283474\",\n \"SemanticContext\": \"Central Nervous System Psychotic episodes at recommended doses rare , overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome.\"\n },\n {\n \"VerbatimTerm\": \"tics\",\n \"Probability\": \"0.0399596393\",\n \"SemanticContext\": \"Amphetamines have been reported to exacerbate motor and phonic tics and Tourette's syndrome.\"\n },\n {\n \"VerbatimTerm\": \"tics\",\n \"Probability\": \"0.0002716184\",\n \"SemanticContext\": \"Therefore clinical evaluation for tics and Tourette's syndrome in children and their families should precede use of stimulant medications.\"\n }\n ]\n },\n {\n \"Term\": \"tourette's disorder\",\n \"MEDDRACode\": \"10044126\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": true,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": true,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": true,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Tourette's syndrome\",\n \"Probability\": \"0.6547732949\",\n \"SemanticContext\": \"Central Nervous System Psychotic episodes at recommended doses rare , overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome.\"\n },\n {\n \"VerbatimTerm\": \"Tourette's syndrome\",\n \"Probability\": \"0.0973490477\",\n \"SemanticContext\": \"Amphetamines have been reported to exacerbate motor and phonic tics and Tourette's syndrome.\"\n },\n {\n \"VerbatimTerm\": \"Tourette's syndrome\",\n \"Probability\": \"0.0004173815\",\n \"SemanticContext\": \"Therefore clinical evaluation for tics and Tourette's syndrome in children and their families should precede use of stimulant medications.\"\n }\n ]\n },\n {\n \"Term\": \"blood lead\",\n \"MEDDRACode\": \"10005639\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": true,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"LEAD\",\n \"Probability\": \"0.10869972407817841\",\n \"SemanticContext\": \"ADMINISTRATION OF AMPHETAMINES FOR PROLONGED PERIODS OF TIME MAY LEAD TO DRUG DEPENDENCE AND MUST BE AVOIDED.\"\n }\n ]\n },\n {\n \"Term\": \"heavy menstrual bleeding\",\n \"MEDDRACode\": \"10085423\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": true,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"PROLONGED PERIODS\",\n \"Probability\": \"0.51478052139282227\",\n \"SemanticContext\": \"ADMINISTRATION OF AMPHETAMINES FOR PROLONGED PERIODS OF TIME MAY LEAD TO DRUG DEPENDENCE AND MUST BE AVOIDED.\"\n }\n ]\n },\n {\n \"Term\": \"sudden death\",\n \"MEDDRACode\": \"10042434\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": true,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Sudden Death\",\n \"Probability\": \"0.9679469466\",\n \"SemanticContext\": \"WARNINGS Serious Cardiovascular Events\\n <text>\\n <paragraph>Sudden Death and Pre-Existing Structural Cardiac Abnormalities or Other Serious Heart Problems</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n <component>\\n <section?ID=\\\"LINK_02ec8821-4647-4a7a-ac4b-e793e13160ff\\\">\\n <id?root=\\\"4384bcfb-52de-41c3-a56d-07d31fa709fd\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>\\n <content?styleCode=\\\"italics\\\">Children and Adolescents</content>\\n </paragraph>\\n <paragraph>Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems.\"\n },\n {\n \"VerbatimTerm\": \"Sudden death\",\n \"Probability\": \"0.8243296146\",\n \"SemanticContext\": \"WARNINGS Serious Cardiovascular Events \\n <text>\\n <paragraph>Sudden Death and Pre-Existing Structural Cardiac Abnormalities or Other Serious Heart Problems</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n <component>\\n <section?ID=\\\"LINK_02ec8821-4647-4a7a-ac4b-e793e13160ff\\\">\\n <id?root=\\\"4384bcfb-52de-41c3-a56d-07d31fa709fd\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>\\n <content?styleCode=\\\"italics\\\">Children and Adolescents</content>\\n </paragraph>\\n <paragraph>Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems.\"\n },\n {\n \"VerbatimTerm\": \"sudden death\",\n \"Probability\": \"0.4367853701\",\n \"SemanticContext\": \"Although some serious heart problems alone carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug \\n <content?styleCode=\\\"italics\\\">see </content>\\n <content?styleCode=\\\"bold\\\">\\n <linkHtml?href=\\\"#LINK_2f759a45-d082-4553-9ba5-71ca27a70c92\\\">CONTRAINDICATIONS</linkHtml>\\n </content> .\"\n },\n {\n \"VerbatimTerm\": \"Sudden deaths\",\n \"Probability\": \"0.9408872724\",\n \"SemanticContext\": \"\\n </paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_efa7df84-150a-4598-9695-25391cd4fe92\\\">\\n <id?root=\\\"62da430a-1692-4410-a818-cc566db86d8f\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>\\n <content?styleCode=\\\"italics\\\">Adults</content>\\n </paragraph>\\n <paragraph>Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD.\"\n },\n {\n \"VerbatimTerm\": \"sudden death\",\n \"Probability\": \"0.0002313852\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_1fb30e55-bf8f-4e7d-a4e5-d8a599e04668\\\">\\n <id?root=\\\"74b99e07-0470-4b26-914b-8de521f757e6\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Assessing Cardiovascular Status in Patients Being Treated with Stimulant Medications</paragraph>\\n <paragraph>Children, adolescents, or adults who are being considered for treatment with stimulant medications should have a careful history including assessment for a family history of sudden death or ventricular arrhythmia and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease e.g., electrocardiogram and echocardiogram .\"\n }\n ]\n },\n {\n \"Term\": \"blood catecholamines\",\n \"MEDDRACode\": \"10005411\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"catecholamine\",\n \"Probability\": \"0.0039569139\",\n \"SemanticContext\": \"Structural Formula: Chemical Structure CLINICAL PHARMACOLOGY Amphetamines are non-catecholamine, sympathomimetic amines with CNS stimulant activity.\"\n }\n ]\n },\n {\n \"Term\": \"blood pressure diastolic\",\n \"MEDDRACode\": \"10005735\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"diastolic blood pressures\",\n \"Probability\": \"0.001049906\",\n \"SemanticContext\": \"Peripheral actions include elevations of systolic and diastolic blood pressures, and weak bronchodilator, and respiratory stimulant action.\"\n }\n ]\n },\n {\n \"Term\": \"dysgeusia\",\n \"MEDDRACode\": \"10013911\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"bitter taste\",\n \"Probability\": \"0.0411615968\",\n \"SemanticContext\": \"It has a slightly bitter taste.\"\n }\n ]\n },\n {\n \"Term\": \"weight increased\",\n \"MEDDRACode\": \"10047899\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"increased weight\",\n \"Probability\": \"0.8998808265\",\n \"SemanticContext\": \"The magnitude of increased weight loss of drug-treated patients over placebo-treated patients is only a fraction of a pound a week.\"\n },\n {\n \"VerbatimTerm\": \"increased weight\",\n \"Probability\": \"0.1249687076\",\n \"SemanticContext\": \"The origins of the increased weight loss due to the various possible drug effects are not established.\"\n },\n {\n \"VerbatimTerm\": \"increased weight\",\n \"Probability\": \"0.0582672656\",\n \"SemanticContext\": \"The amount of weight loss associated with the use of an \\\"anorectic\\\" drug varies from trial to trial, and the increased weight loss appears to be related in part to variables other than the drug prescribed, such as the physician-investigator, the population treated, and the diet prescribed.\"\n }\n ]\n },\n {\n \"Term\": \"obesity\",\n \"MEDDRACode\": \"10029883\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"obesity\",\n \"Probability\": \"0.0005571842\",\n \"SemanticContext\": \"Drugs in this class used in obesity are commonly known as \\\"anorectics\\\" or \\\"anorexigenics.\\\"\"\n },\n {\n \"VerbatimTerm\": \"obesity\",\n \"Probability\": \"0.0839181244\",\n \"SemanticContext\": \"It has not been established, however, that the action of such drugs in treating obesity is primarily one of appetite suppression.\"\n },\n {\n \"VerbatimTerm\": \"obesity\",\n \"Probability\": \"0.0007050037\",\n \"SemanticContext\": \"The natural history of obesity is measured in years, whereas the studies cited are restricted to few weeks duration; thus, the total impact of drug-induced weight loss over that of diet alone must be considered clinically limited.\"\n },\n {\n \"VerbatimTerm\": \"Obesity\",\n \"Probability\": \"0.0001922548\",\n \"SemanticContext\": \"Exogenous Obesity Usual dosage is up to 30 mg daily, taken in divided doses of 5 to 10 mg, 30 to 60 minutes before meals.\"\n },\n {\n \"VerbatimTerm\": \"Obesity\",\n \"Probability\": \"0.0014308393\",\n \"SemanticContext\": \"Exogenous Obesity as a short term a few weeks adjunct in a regimen of weight reduction based on caloric restriction for patients refractory to alternative therapy, e.g., repeated diets, group programs, and other drugs.\"\n }\n ]\n },\n {\n \"Term\": \"weight\",\n \"MEDDRACode\": \"10047890\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"weight\",\n \"Probability\": \"3.3108E-05\",\n \"SemanticContext\": \"Adult obese subjects instructed in dietary management and treated with \\\"anorectic\\\" drugs lose more weight on the average than these treated with placebo and diet, as determined in relatively short-term clinical trials.\"\n },\n {\n \"VerbatimTerm\": \"weight\",\n \"Probability\": \"2.40198E-05\",\n \"SemanticContext\": \"Exogenous Obesity as a short term a few weeks adjunct in a regimen of weight reduction based on caloric restriction for patients refractory to alternative therapy, e.g., repeated diets, group programs, and other drugs.\"\n },\n {\n \"VerbatimTerm\": \"weight\",\n \"Probability\": \"0.0001266599\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_6fd66f82-1c94-42dd-be7a-b55d4bcc4059\\\">\\n <id?root=\\\"71cacc65-1f33-4908-8a9f-bf6ed58b6dfd\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title>Long-Term Suppression of Growth Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated children over 36 months to the ages of 10 to 13 years , suggests that consistently medicated children i.e., treatment for 7 days per week throughout the year have a temporary slowing in growth rate on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years , without evidence of growth rebound during this period of development.\"\n },\n {\n \"VerbatimTerm\": \"weight\",\n \"Probability\": \"1.17364E-05\",\n \"SemanticContext\": \"Therefore, growth should be monitored during treatment with stimulants, and patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted.\"\n }\n ]\n },\n {\n \"Term\": \"crigler-najjar syndrome\",\n \"MEDDRACode\": \"10011386\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"CNS\",\n \"Probability\": \"0.0067647994\",\n \"SemanticContext\": \"Structural Formula: Chemical Structure CLINICAL PHARMACOLOGY Amphetamines are non-catecholamine, sympathomimetic amines with CNS stimulant activity.\"\n },\n {\n \"VerbatimTerm\": \"CNS\",\n \"Probability\": \"0.0730628073\",\n \"SemanticContext\": \"The l-isomer is more potent than the d-isomer in cardiovascular activity, but much less potent in causing CNS excitatory effects.\"\n },\n {\n \"VerbatimTerm\": \"CNS\",\n \"Probability\": \"0.0140513182\",\n \"SemanticContext\": \"WARNINGS Serious Cardiovascular Events \\n <text>\\n <paragraph>Sudden Death and Pre-Existing Structural Cardiac Abnormalities or Other Serious Heart Problems</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n <component>\\n <section?ID=\\\"LINK_02ec8821-4647-4a7a-ac4b-e793e13160ff\\\">\\n <id?root=\\\"4384bcfb-52de-41c3-a56d-07d31fa709fd\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>\\n <content?styleCode=\\\"italics\\\">Children and Adolescents</content>\\n </paragraph>\\n <paragraph>Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems.\"\n }\n ]\n },\n {\n \"Term\": \"arteriosclerosis\",\n \"MEDDRACode\": \"10003210\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": true,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"arteriosclerosis\",\n \"Probability\": \"0.0016159415\",\n \"SemanticContext\": \"CONTRAINDICATIONS Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines.\"\n }\n ]\n },\n {\n \"Term\": \"hypersensitivity\",\n \"MEDDRACode\": \"10020751\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": true,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"hypersensitivity\",\n \"Probability\": \"0.0041890144\",\n \"SemanticContext\": \"CONTRAINDICATIONS Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines.\"\n }\n ]\n },\n {\n \"Term\": \"hyperthyroidism\",\n \"MEDDRACode\": \"10020850\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": true,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"hyperthyroidism\",\n \"Probability\": \"0.0013562441\",\n \"SemanticContext\": \"CONTRAINDICATIONS Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines.\"\n }\n ]\n },\n {\n \"Term\": \"hypertensive crisis\",\n \"MEDDRACode\": \"10020802\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": true,\n \"DrugInteractions\": true,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"hypertensive crises\",\n \"Probability\": \"0.0834576488\",\n \"SemanticContext\": \"During or within 14 days following the administration of monoamine oxidase inhibitors hypertensive crises may result .\"\n },\n {\n \"VerbatimTerm\": \"hypertensive crisis\",\n \"Probability\": \"0.0819043219\",\n \"SemanticContext\": \"This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; this can cause headaches and other signs of hypertensive crisis.\"\n }\n ]\n },\n {\n \"Term\": \"hypertension\",\n \"MEDDRACode\": \"10020772\",\n \"Overdose\": true,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": true,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"hypertension\",\n \"Probability\": \"0.0024989247\",\n \"SemanticContext\": \"CONTRAINDICATIONS Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines.\"\n },\n {\n \"VerbatimTerm\": \"hypertension\",\n \"Probability\": \"0.9981671572\",\n \"SemanticContext\": \"Cardiovascular effects include arrhythmias, hypertension, or hypotension and circulatory collapse.\"\n },\n {\n \"VerbatimTerm\": \"hypertension\",\n \"Probability\": \"6.92783E-05\",\n \"SemanticContext\": \"If acute, severe hypertension complicates amphetamine overdosage, administration of intravenous phentolamine has been suggested.\"\n },\n {\n \"VerbatimTerm\": \"Hypertension\",\n \"Probability\": \"0.6910169125\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_a8c33687-9be4-4bbe-b513-5ea06f35844b\\\">\\n <id?root=\\\"ae542c3e-c674-44f7-be43-483a5ae2fe56\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Hypertension and Other Cardiovascular Conditions</paragraph>\\n <paragraph>Stimulant medications cause a modest increase in average blood pressure about 2 to 4 mmHg and average heart rate about 3 to 6 bpm , and individuals may have larger increases.\"\n },\n {\n \"VerbatimTerm\": \"hypertension\",\n \"Probability\": \"0.0051397085\",\n \"SemanticContext\": \"Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate, e.g., those with pre-existing hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia \\n <content?styleCode=\\\"italics\\\">see </content>\\n <content?styleCode=\\\"bold\\\">\\n <linkHtml?href=\\\"#LINK_2f759a45-d082-4553-9ba5-71ca27a70c92\\\">CONTRAINDICATIONS</linkHtml>\\n </content> .\"\n },\n {\n \"VerbatimTerm\": \"hypertension\",\n \"Probability\": \"1.99253E-05\",\n \"SemanticContext\": \"PRECAUTIONS General Caution is to be exercised in prescribing amphetamines for patients with even mild hypertension.\"\n }\n ]\n },\n {\n \"Term\": \"agitation\",\n \"MEDDRACode\": \"10001497\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": true,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Agitated\",\n \"Probability\": \"0.02555722\",\n \"SemanticContext\": \"Agitated states.\"\n },\n {\n \"VerbatimTerm\": \"agitation\",\n \"Probability\": \"0.9811751246\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n },\n {\n \"VerbatimTerm\": \"agitation\",\n \"Probability\": \"0.8237032294\",\n \"SemanticContext\": \"Also, these infants may experience symptoms of withdrawal as demonstrated by dysphoria, including agitation, and significant lassitude.\"\n }\n ]\n },\n {\n \"Term\": \"narcolepsy\",\n \"MEDDRACode\": \"10028713\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Narcolepsy\",\n \"Probability\": \"0.0051219761\",\n \"SemanticContext\": \"Narcolepsy Usual dose is 5 to 60 milligrams per day in divided doses depending on the individual patient response.\"\n },\n {\n \"VerbatimTerm\": \"Narcolepsy\",\n \"Probability\": \"0.0112720728\",\n \"SemanticContext\": \"Narcolepsy seldom occurs in children under 12 years of age; however, when it does, amphetamine sulfate tablets may be used.\"\n },\n {\n \"VerbatimTerm\": \"Narcolepsy\",\n \"Probability\": \"0.6483716965\",\n \"SemanticContext\": \"INDICATIONS AND USAGE Amphetamine sulfate tablets are indicated for: Narcolepsy Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures psychological, educational, social for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.\"\n }\n ]\n },\n {\n \"Term\": \"attention deficit hyperactivity disorder\",\n \"MEDDRACode\": \"10083622\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": true,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": true,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Attention Deficit Disorder\",\n \"Probability\": \"0.0032350123\",\n \"SemanticContext\": \"Attention Deficit Disorder with Hyperactivity Not recommended for children under 3 years of age.\"\n },\n {\n \"VerbatimTerm\": \"Attention Deficit Disorder\",\n \"Probability\": \"0.2751638889\",\n \"SemanticContext\": \"INDICATIONS AND USAGE Amphetamine sulfate tablets are indicated for: Narcolepsy Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures psychological, educational, social for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.\"\n },\n {\n \"VerbatimTerm\": \"ADHD\",\n \"Probability\": \"0.0424323678\",\n \"SemanticContext\": \"\\n </paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_efa7df84-150a-4598-9695-25391cd4fe92\\\">\\n <id?root=\\\"62da430a-1692-4410-a818-cc566db86d8f\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>\\n <content?styleCode=\\\"italics\\\">Adults</content>\\n </paragraph>\\n <paragraph>Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD.\"\n },\n {\n \"VerbatimTerm\": \"ADHD\",\n \"Probability\": \"0.0084741712\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_48bbdf15-0d99-4bde-afb6-c20acefcb8cc\\\">\\n <id?root=\\\"f1101b74-266a-4642-9be5-d382b24dbd46\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Bipolar Illness</paragraph>\\n <paragraph>Particular care should be taken in using stimulants to treat ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/manic episode in such patients.\"\n },\n {\n \"VerbatimTerm\": \"ADHD\",\n \"Probability\": \"0.220174253\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_f4651d77-f40c-4521-8978-212a8266a211\\\">\\n <id?root=\\\"19a37e74-d56d-4be3-8728-0ca36865c042\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Aggression</paragraph>\\n <paragraph>Aggressive behavior or hostility is often observed in children and adolescents with ADHD, and has been reported in clinical trials and the postmarketing experience of some medications indicated for the treatment of ADHD.\"\n },\n {\n \"VerbatimTerm\": \"ADHD\",\n \"Probability\": \"0.0013663769\",\n \"SemanticContext\": \"Although there is no systematic evidence that stimulants cause aggressive behavior or hostility, patients beginning treatment for ADHD should be monitored for the appearance of or worsening of aggressive behavior or hostility.\"\n },\n {\n \"VerbatimTerm\": \"ADHD\",\n \"Probability\": \"0.0671566427\",\n \"SemanticContext\": \"Peripheral Vasculopathy, Including Raynaud's Phenomenon Stimulants, including amphetamine sulfate tablets, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon.\"\n },\n {\n \"VerbatimTerm\": \"ADHD\",\n \"Probability\": \"0.0001003763\",\n \"SemanticContext\": \"Careful observation for digital changes is necessary during treatment with ADHD stimulants.\"\n },\n {\n \"VerbatimTerm\": \"Attention Deficit Disorder\",\n \"Probability\": \"0.0020591319\",\n \"SemanticContext\": \"Amphetamines are not recommended for use as anorectic agents in children under 12 years of age, or in children under 3 years of age with Attention Deficit Disorder with Hyperactivity described under INDICATIONS AND USAGE.\"\n },\n {\n \"VerbatimTerm\": \"Attention Deficit Disorder\",\n \"Probability\": \"0.0038250983\",\n \"SemanticContext\": \"Drug treatment is not indicated in all cases of Attention Deficit Disorder with Hyperactivity and should be considered only in light of the complete history and evaluation of the child.\"\n }\n ]\n },\n {\n \"Term\": \"hypotension\",\n \"MEDDRACode\": \"10021097\",\n \"Overdose\": true,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": true,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"hypotensive\",\n \"Probability\": \"0.3240212798\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_fc86a964-4d97-4f1c-be7e-671bd4371fce\\\">\\n <id?root=\\\"8e77e33b-029b-4377-be20-f6cbaa1a4114\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Antihypertensives</paragraph>\\n <paragraph>Amphetamines may antagonize the hypotensive effects of antihypertensives.\"\n },\n {\n \"VerbatimTerm\": \"hypotensive\",\n \"Probability\": \"0.4972122312\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_953e50a6-5406-4e13-922a-08832b64a625\\\">\\n <id?root=\\\"538e95d0-c7f4-4a71-9d6e-ff89261161a5\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Veratrum Alkaloids</paragraph>\\n <paragraph>Amphetamines inhibit the hypotensive effect of veratrum alkaloids.\"\n },\n {\n \"VerbatimTerm\": \"hypotension\",\n \"Probability\": \"0.9990583062\",\n \"SemanticContext\": \"Cardiovascular effects include arrhythmias, hypertension, or hypotension and circulatory collapse.\"\n }\n ]\n },\n {\n \"Term\": \"seizure\",\n \"MEDDRACode\": \"10039906\",\n \"Overdose\": true,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": true,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"convulsions\",\n \"Probability\": \"0.9498666525\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_28936037-7ead-4682-8705-37fb3f3c9f88\\\">\\n <id?root=\\\"47fd7216-359c-4ecc-87c9-973163c17e56\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Propoxyphene</paragraph>\\n <paragraph>In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.\"\n },\n {\n \"VerbatimTerm\": \"convulsions\",\n \"Probability\": \"0.950570941\",\n \"SemanticContext\": \"Fatal poisoning is usually preceded by convulsions and coma.\"\n },\n {\n \"VerbatimTerm\": \"Seizures\",\n \"Probability\": \"0.0547896028\",\n \"SemanticContext\": \"Seizures There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures.\"\n },\n {\n \"VerbatimTerm\": \"seizures\",\n \"Probability\": \"0.0026230812\",\n \"SemanticContext\": \"Seizures There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures.\"\n },\n {\n \"VerbatimTerm\": \"seizures\",\n \"Probability\": \"0.1359867454\",\n \"SemanticContext\": \"In the presence of seizures, the drug should be discontinued.\"\n },\n {\n \"VerbatimTerm\": \"seizures\",\n \"Probability\": \"0.9924521446\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n }\n ]\n },\n {\n \"Term\": \"analgesic therapy\",\n \"MEDDRACode\": \"10053469\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": true,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"analgesic effect\",\n \"Probability\": \"0.0021753609\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_9f51c7bd-71d3-4ecd-97cb-399327d49663\\\">\\n <id?root=\\\"0c4bbe4a-8010-4b90-98cf-3f86e794a71e\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Meperidine</paragraph>\\n <paragraph>Amphetamines potentiate the analgesic effect of meperidine.\"\n }\n ]\n },\n {\n \"Term\": \"blood bicarbonate\",\n \"MEDDRACode\": \"10005357\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": true,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"bicarbonate\",\n \"Probability\": \"0.000210762\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_3e5cc985-b9d1-46d7-bcfb-5d9f43fddbae\\\">\\n <id?root=\\\"100e9072-364f-4f20-a398-cca861e8c1c1\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Alkalinizing Agents</paragraph>\\n <paragraph>Gastrointestinal alkalinizing agents sodium bicarbonate, etc. increase absorption of amphetamines.\"\n }\n ]\n },\n {\n \"Term\": \"blood chloride\",\n \"MEDDRACode\": \"10005416\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": true,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"chloride\",\n \"Probability\": \"0.0001687706\",\n \"SemanticContext\": \"Urinary acidifying agents ammonium chloride, sodium acid phosphate, etc. increase concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.\"\n }\n ]\n },\n {\n \"Term\": \"blood phosphorus\",\n \"MEDDRACode\": \"10005717\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": true,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"phosphate\",\n \"Probability\": \"0.0005083382\",\n \"SemanticContext\": \"Urinary acidifying agents ammonium chloride, sodium acid phosphate, etc. increase concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.\"\n }\n ]\n },\n {\n \"Term\": \"blood sodium\",\n \"MEDDRACode\": \"10005799\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": true,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"sodium\",\n \"Probability\": \"0.0005560815\",\n \"SemanticContext\": \"Urinary acidifying agents ammonium chloride, sodium acid phosphate, etc. increase concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.\"\n },\n {\n \"VerbatimTerm\": \"sodium\",\n \"Probability\": \"0.0002723932\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_3e5cc985-b9d1-46d7-bcfb-5d9f43fddbae\\\">\\n <id?root=\\\"100e9072-364f-4f20-a398-cca861e8c1c1\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Alkalinizing Agents</paragraph>\\n <paragraph>Gastrointestinal alkalinizing agents sodium bicarbonate, etc. increase absorption of amphetamines.\"\n }\n ]\n },\n {\n \"Term\": \"central nervous system stimulation\",\n \"MEDDRACode\": \"10061444\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": true,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"CNS stimulation\",\n \"Probability\": \"0.7522311211\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_28936037-7ead-4682-8705-37fb3f3c9f88\\\">\\n <id?root=\\\"47fd7216-359c-4ecc-87c9-973163c17e56\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Propoxyphene</paragraph>\\n <paragraph>In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.\"\n }\n ]\n },\n {\n \"Term\": \"drug interaction\",\n \"MEDDRACode\": \"10013710\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": true,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Drug Interactions\",\n \"Probability\": \"0.0006350577\",\n \"SemanticContext\": \"Drug Interactions \\n <text>\\n <paragraph>Acidifying Agents</paragraph>\\n <paragraph>Gastrointestinal acidifying agents guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc. lower absorption of amphetamines.\"\n },\n {\n \"VerbatimTerm\": \"Interactions\",\n \"Probability\": \"0.0017514229\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n </section>\\n <section?ID=\\\"LINK_3e0f5ebc-7163-495b-9c6f-1034630fb209\\\">\\n <id?root=\\\"ab9fac15-a26a-4e92-b657-3ae851c4208c\\\"?/>\\n <code?code=\\\"34074-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"DRUG?&?OR?LABORATORY?TEST?INTERACTIONS?SECTION\\\"?/>\\n <title>Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels.\"\n },\n {\n \"VerbatimTerm\": \"DRUG INTERACTIONS\",\n \"Probability\": \"5.04697E-05\",\n \"SemanticContext\": \"Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors MAOIs , selective serotonin reuptake inhibitors SSRIs , serotonin norepinephrine reuptake inhibitors SNRIs , triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort see DRUG INTERACTIONS .\"\n },\n {\n \"VerbatimTerm\": \"pharmacokinetic interaction\",\n \"Probability\": \"0.0001063299\",\n \"SemanticContext\": \"The potential for a pharmacokinetic interaction exists with the co-administration of CYP2D6 inhibitors which may increase the risk with increased exposure to amphetamine sulfate tablets.\"\n },\n {\n \"VerbatimTerm\": \"DRUG INTERACTIONS\",\n \"Probability\": \"0.0003766119\",\n \"SemanticContext\": \"In these situations, consider an alternative non-serotonergic drug or an alternative drug that does not inhibit CYP2D6 see DRUG INTERACTIONS .\"\n },\n {\n \"VerbatimTerm\": \"Drug Interactions\",\n \"Probability\": \"0.0003663599\",\n \"SemanticContext\": \"\\n </item>\\n </list>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_98f61d75-3c2e-429d-9225-8c171ea8fcb6\\\">\\n <id?root=\\\"c0b0a338-b468-47e1-81f5-733cab50e6b6\\\"?/>\\n <code?code=\\\"34073-7\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"DRUG?INTERACTIONS?SECTION\\\"?/>\\n <title>Drug Interactions \\n <text>\\n <paragraph>Acidifying Agents</paragraph>\\n <paragraph>Gastrointestinal acidifying agents guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc. lower absorption of amphetamines.\"\n },\n {\n \"VerbatimTerm\": \"Interactions\",\n \"Probability\": \"0.0017514229\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_3e0f5ebc-7163-495b-9c6f-1034630fb209\\\">\\n <id?root=\\\"ab9fac15-a26a-4e92-b657-3ae851c4208c\\\"?/>\\n <code?code=\\\"34074-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"DRUG?&?OR?LABORATORY?TEST?INTERACTIONS?SECTION\\\"?/>\\n <title>Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels.\"\n }\n ]\n },\n {\n \"Term\": \"hyperthermia malignant\",\n \"MEDDRACode\": \"10020844\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": true,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"malignant hyperpyrexia\",\n \"Probability\": \"0.3858418465\",\n \"SemanticContext\": \"A variety of neurological toxic effects and malignant hyperpyrexia can occur, sometimes with fatal results.\"\n }\n ]\n },\n {\n \"Term\": \"laboratory test\",\n \"MEDDRACode\": \"10059938\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": true,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Laboratory Test\",\n \"Probability\": \"0.0004478097\",\n \"SemanticContext\": \"\\n </paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n</section>\\n<section?ID=\\\"LINK_3e0f5ebc-7163-495b-9c6f-1034630fb209\\\">\\n <id?root=\\\"ab9fac15-a26a-4e92-b657-3ae851c4208c\\\"?/>\\n <code?code=\\\"34074-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"DRUG?&?OR?LABORATORY?TEST?INTERACTIONS?SECTION\\\"?/>\\n <title>Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels.\"\n },\n {\n \"VerbatimTerm\": \"Laboratory Test\",\n \"Probability\": \"0.0004347861\",\n \"SemanticContext\": \"\\n </paragraph>\\n</text>\\n<effectiveTime?value=\\\"20220228\\\"?/>\\n</section>\\n</component>\\n</section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_3e0f5ebc-7163-495b-9c6f-1034630fb209\\\">\\n <id?root=\\\"ab9fac15-a26a-4e92-b657-3ae851c4208c\\\"?/>\\n <code?code=\\\"34074-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"DRUG?&?OR?LABORATORY?TEST?INTERACTIONS?SECTION\\\"?/>\\n <title>Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels.\"\n }\n ]\n },\n {\n \"Term\": \"norepinephrine\",\n \"MEDDRACode\": \"10050925\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": true,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"norepinephrine\",\n \"Probability\": \"0.0096471608\",\n \"SemanticContext\": \"Examples of serotonergic drugs include selective serotonin reuptake inhibitors SSRI , serotonin norepinephrine reuptake inhibitors SNRI , triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort.\"\n },\n {\n \"VerbatimTerm\": \"norepinephrine\",\n \"Probability\": \"0.0009447932\",\n \"SemanticContext\": \"This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; this can cause headaches and other signs of hypertensive crisis.\"\n },\n {\n \"VerbatimTerm\": \"norepinephrine\",\n \"Probability\": \"0.0115564466\",\n \"SemanticContext\": \"\\n </paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n</section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_23311580-d20a-493e-91c1-35257ab2d9f0\\\">\\n <id?root=\\\"9932814a-a838-4aad-ad63-1b8d3393d678\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Chlorpromazine</paragraph>\\n <paragraph>Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamine, and can be used to treat amphetamine poisoning.\"\n },\n {\n \"VerbatimTerm\": \"norepinephrine\",\n \"Probability\": \"0.0047973096\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_47aad24a-4ca0-4d46-bd0b-74f20217b414\\\">\\n <id?root=\\\"601ba4a0-eecf-4415-9d3f-79a0e4da6910\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Haloperidol</paragraph>\\n <paragraph>Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.\"\n },\n {\n \"VerbatimTerm\": \"Norepinephrine\",\n \"Probability\": \"0.0083833635\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_7c41ee9a-48e8-4283-9ed2-4ccf7ad020ac\\\">\\n <id?root=\\\"05a6181c-979f-4e0e-a60b-005d47aff6c2\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Norepinephrine</paragraph>\\n <paragraph>Amphetamines enhance the adrenergic effect of norepinephrine.\"\n },\n {\n \"VerbatimTerm\": \"norepinephrine\",\n \"Probability\": \"0.0036913455\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_7c41ee9a-48e8-4283-9ed2-4ccf7ad020ac\\\">\\n <id?root=\\\"05a6181c-979f-4e0e-a60b-005d47aff6c2\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Norepinephrine</paragraph>\\n <paragraph>Amphetamines enhance the adrenergic effect of norepinephrine.\"\n },\n {\n \"VerbatimTerm\": \"norepinephrine\",\n \"Probability\": \"0.0037450194\",\n \"SemanticContext\": \"Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors MAOIs , selective serotonin reuptake inhibitors SSRIs , serotonin norepinephrine reuptake inhibitors SNRIs , triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort see DRUG INTERACTIONS .\"\n }\n ]\n },\n {\n \"Term\": \"serotonin syndrome\",\n \"MEDDRACode\": \"10040108\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": true,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"serotonin syndrome\",\n \"Probability\": \"0.2844109535\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_1459a591-1227-47da-afdc-16af572fc22a\\\">\\n <id?root=\\\"4ff2140e-4071-4b66-a91b-ceb4a8847628\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>CYP2D6 Inhibitors</paragraph>\\n <paragraph>The concomitant use of amphetamine sulfate tablets and CYP2D6 inhibitors may increase the exposure of amphetamine sulfate tablets compared to the use of the drug alone and increase the risk of serotonin syndrome.\"\n },\n {\n \"VerbatimTerm\": \"serotonin syndrome\",\n \"Probability\": \"0.0007681251\",\n \"SemanticContext\": \"Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome particularly during amphetamine sulfate tablets initiation and after a dosage increase.\"\n },\n {\n \"VerbatimTerm\": \"serotonin syndrome\",\n \"Probability\": \"0.0099193454\",\n \"SemanticContext\": \"If serotonin syndrome occurs, discontinue amphetamine sulfate tablets and the CYP2D6 inhibitor \\n <content?styleCode=\\\"italics\\\">see </content>\\n <content?styleCode=\\\"bold\\\">\\n <linkHtml?href=\\\"#LINK_7f88cfb8-7f79-43fb-bd9e-880eca652366\\\">WARNINGS</linkHtml>\\n </content>\\n <content?styleCode=\\\"italics\\\">and </content>\\n <content?styleCode=\\\"bold\\\">\\n <linkHtml?href=\\\"#LINK_896c3ec4-b768-4f11-a4c0-6af58c9b96fe\\\">OVERDOSAGE</linkHtml>\\n </content> .\"\n },\n {\n \"VerbatimTerm\": \"serotonin syndrome\",\n \"Probability\": \"0.4218759537\",\n \"SemanticContext\": \"\\n </paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_1679d416-fe26-4064-b234-fcb882c84b3b\\\">\\n <id?root=\\\"ebe2103c-bb81-4d27-9622-29f3ebf7bfb2\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Serotonergic Drugs</paragraph>\\n <paragraph>The concomitant use of amphetamine sulfate tablets and serotonergic drugs increases the risk of serotonin syndrome.\"\n },\n {\n \"VerbatimTerm\": \"serotonin syndrome\",\n \"Probability\": \"0.0004289746\",\n \"SemanticContext\": \"Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during amphetamine sulfate tablets initiation or dosage increase.\"\n },\n {\n \"VerbatimTerm\": \"serotonin syndrome\",\n \"Probability\": \"0.0132805705\",\n \"SemanticContext\": \"If serotonin syndrome occurs, discontinue amphetamine sulfate tablets and the concomitant serotonergic drug s \\n <content?styleCode=\\\"italics\\\">see </content>\\n <content?styleCode=\\\"bold\\\">\\n <linkHtml?href=\\\"#LINK_7f88cfb8-7f79-43fb-bd9e-880eca652366\\\">WARNINGS</linkHtml>\\n </content>\\n <content?styleCode=\\\"italics\\\">and </content>\\n <content?styleCode=\\\"bold\\\">\\n <linkHtml?href=\\\"#LINK_c898802f-0a06-4b24-8f1c-6160b329033a\\\">PRECAUTIONS</linkHtml>\\n </content> .\"\n },\n {\n \"VerbatimTerm\": \"Serotonin Syndrome\",\n \"Probability\": \"0.9297687411\",\n \"SemanticContext\": \"Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors MAOIs , selective serotonin reuptake inhibitors SSRIs , serotonin norepinephrine reuptake inhibitors SNRIs , triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort see DRUG INTERACTIONS .\"\n },\n {\n \"VerbatimTerm\": \"Syndrome Serotonin\",\n \"Probability\": \"0.8567962646\",\n \"SemanticContext\": \"Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors MAOIs , selective serotonin reuptake inhibitors SSRIs , serotonin norepinephrine reuptake inhibitors SNRIs , triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort see DRUG INTERACTIONS .\"\n },\n {\n \"VerbatimTerm\": \"Serotonin syndrome\",\n \"Probability\": \"0.7974624634\",\n \"SemanticContext\": \"Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors MAOIs , selective serotonin reuptake inhibitors SSRIs , serotonin norepinephrine reuptake inhibitors SNRIs , triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort see DRUG INTERACTIONS .\"\n },\n {\n \"VerbatimTerm\": \"Serotonin syndrome\",\n \"Probability\": \"0.9139000773\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n },\n {\n \"VerbatimTerm\": \"serotonin syndrome\",\n \"Probability\": \"0.0011074245\",\n \"SemanticContext\": \"If concomitant use of amphetamine sulfate tablets with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate amphetamine sulfate tablets with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome.\"\n }\n ]\n },\n {\n \"Term\": \"vitamin c\",\n \"MEDDRACode\": \"10047620\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": true,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"ascorbic acid\",\n \"Probability\": \"0.0001870394\",\n \"SemanticContext\": \"Drug Interactions\\n <text>\\n <paragraph>Acidifying Agents</paragraph>\\n <paragraph>Gastrointestinal acidifying agents guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc. lower absorption of amphetamines.\"\n },\n {\n \"VerbatimTerm\": \"ascorbic acid\",\n \"Probability\": \"0.0007434785\",\n \"SemanticContext\": \"\\n </item>\\n </list>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n</section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_98f61d75-3c2e-429d-9225-8c171ea8fcb6\\\">\\n <id?root=\\\"c0b0a338-b468-47e1-81f5-733cab50e6b6\\\"?/>\\n <code?code=\\\"34073-7\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"DRUG?INTERACTIONS?SECTION\\\"?/>\\n <title>Drug Interactions \\n <text>\\n <paragraph>Acidifying Agents</paragraph>\\n <paragraph>Gastrointestinal acidifying agents guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc. lower absorption of amphetamines.\"\n }\n ]\n },\n {\n \"Term\": \"affect lability\",\n \"MEDDRACode\": \"10054196\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"emotional lability\",\n \"Probability\": \"0.2377811372\",\n \"SemanticContext\": \"INDICATIONS AND USAGE Amphetamine sulfate tablets are indicated for: Narcolepsy Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures psychological, educational, social for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.\"\n }\n ]\n },\n {\n \"Term\": \"distractibility\",\n \"MEDDRACode\": \"10013486\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"distractibility\",\n \"Probability\": \"0.4058155119\",\n \"SemanticContext\": \"INDICATIONS AND USAGE Amphetamine sulfate tablets are indicated for: Narcolepsy Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures psychological, educational, social for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.\"\n }\n ]\n },\n {\n \"Term\": \"electroencephalogram abnormal\",\n \"MEDDRACode\": \"10014408\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"abnormal EEG\",\n \"Probability\": \"0.4380988181\",\n \"SemanticContext\": \"Nonlocalizing soft neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or not be warranted.\"\n }\n ]\n },\n {\n \"Term\": \"learning disability\",\n \"MEDDRACode\": \"10024092\",\n \"Overdose\": false,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": true,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"learning disability\",\n \"Probability\": \"0.0599977672\",\n \"SemanticContext\": \"Nonlocalizing soft neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or not be warranted.\"\n }\n ]\n },\n {\n \"Term\": \"abdominal pain\",\n \"MEDDRACode\": \"10000081\",\n \"Overdose\": true,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"abdominal cramps\",\n \"Probability\": \"0.9880363941\",\n \"SemanticContext\": \"Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps.\"\n }\n ]\n },\n {\n \"Term\": \"arrhythmia\",\n \"MEDDRACode\": \"10003119\",\n \"Overdose\": true,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"arrhythmias\",\n \"Probability\": \"0.9988046885\",\n \"SemanticContext\": \"Cardiovascular effects include arrhythmias, hypertension, or hypotension and circulatory collapse.\"\n }\n ]\n },\n {\n \"Term\": \"barbiturates\",\n \"MEDDRACode\": \"10063229\",\n \"Overdose\": true,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"barbiturate\",\n \"Probability\": \"0.0848143101\",\n \"SemanticContext\": \"Treatment Management of acute amphetamine intoxication is largely symptomatic and includes gastric lavage and sedation with a barbiturate.\"\n }\n ]\n },\n {\n \"Term\": \"blood pressure decreased\",\n \"MEDDRACode\": \"10005734\",\n \"Overdose\": true,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"drop in blood pressure\",\n \"Probability\": \"0.0026135445\",\n \"SemanticContext\": \"However, a gradual drop in blood pressure will usually result when sufficient sedation has been achieved.\"\n }\n ]\n },\n {\n \"Term\": \"circulatory collapse\",\n \"MEDDRACode\": \"10009192\",\n \"Overdose\": true,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"circulatory collapse\",\n \"Probability\": \"0.9944646955\",\n \"SemanticContext\": \"Cardiovascular effects include arrhythmias, hypertension, or hypotension and circulatory collapse.\"\n }\n ]\n },\n {\n \"Term\": \"confusional state\",\n \"MEDDRACode\": \"10010305\",\n \"Overdose\": true,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"confusion\",\n \"Probability\": \"0.9155395627\",\n \"SemanticContext\": \"Symptoms Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rhabdomyolysis, rapid respiration, hyperpyrexia, confusion, assaultiveness, hallucinations, panic states.\"\n }\n ]\n },\n {\n \"Term\": \"gastric lavage\",\n \"MEDDRACode\": \"10017792\",\n \"Overdose\": true,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"gastric lavage\",\n \"Probability\": \"0.0229946077\",\n \"SemanticContext\": \"Treatment Management of acute amphetamine intoxication is largely symptomatic and includes gastric lavage and sedation with a barbiturate.\"\n }\n ]\n },\n {\n \"Term\": \"haemodialysis\",\n \"MEDDRACode\": \"10018875\",\n \"Overdose\": true,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"hemodialysis\",\n \"Probability\": \"5.71143E-05\",\n \"SemanticContext\": \"Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendation in this regard.\"\n }\n ]\n },\n {\n \"Term\": \"hyperpyrexia\",\n \"MEDDRACode\": \"10020741\",\n \"Overdose\": true,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"hyperpyrexia\",\n \"Probability\": \"0.9664319158\",\n \"SemanticContext\": \"Symptoms Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rhabdomyolysis, rapid respiration, hyperpyrexia, confusion, assaultiveness, hallucinations, panic states.\"\n }\n ]\n },\n {\n \"Term\": \"peritoneal dialysis\",\n \"MEDDRACode\": \"10034660\",\n \"Overdose\": true,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"peritoneal dialysis\",\n \"Probability\": \"1.81101E-05\",\n \"SemanticContext\": \"Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendation in this regard.\"\n }\n ]\n },\n {\n \"Term\": \"sedation\",\n \"MEDDRACode\": \"10039897\",\n \"Overdose\": true,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"sedation\",\n \"Probability\": \"0.3964724839\",\n \"SemanticContext\": \"Treatment Management of acute amphetamine intoxication is largely symptomatic and includes gastric lavage and sedation with a barbiturate.\"\n },\n {\n \"VerbatimTerm\": \"sedation\",\n \"Probability\": \"0.0065217316\",\n \"SemanticContext\": \"However, a gradual drop in blood pressure will usually result when sufficient sedation has been achieved.\"\n }\n ]\n },\n {\n \"Term\": \"toxicity to various agents\",\n \"MEDDRACode\": \"10070863\",\n \"Overdose\": true,\n \"Warnings\": false,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"toxic symptoms\",\n \"Probability\": \"0.036314249\",\n \"SemanticContext\": \"While toxic symptoms occasionally occur as an idiosyncrasy at doses as low as 2 mg, they are rare with doses of less than 15 mg; 30 mg can produce severe reactions, yet doses of 400 to 500 mg are not necessarily fatal.\"\n },\n {\n \"VerbatimTerm\": \"acute amphetamine intoxication\",\n \"Probability\": \"0.0119083226\",\n \"SemanticContext\": \"Treatment Management of acute amphetamine intoxication is largely symptomatic and includes gastric lavage and sedation with a barbiturate.\"\n }\n ]\n },\n {\n \"Term\": \"coma\",\n \"MEDDRACode\": \"10010071\",\n \"Overdose\": true,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"coma\",\n \"Probability\": \"0.9143260717\",\n \"SemanticContext\": \"Fatal poisoning is usually preceded by convulsions and coma.\"\n },\n {\n \"VerbatimTerm\": \"coma\",\n \"Probability\": \"0.9898045063\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n }\n ]\n },\n {\n \"Term\": \"hallucination\",\n \"MEDDRACode\": \"10019063\",\n \"Overdose\": true,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"hallucinations\",\n \"Probability\": \"0.9368496537\",\n \"SemanticContext\": \"Symptoms Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rhabdomyolysis, rapid respiration, hyperpyrexia, confusion, assaultiveness, hallucinations, panic states.\"\n },\n {\n \"VerbatimTerm\": \"hallucinations\",\n \"Probability\": \"0.7388604283\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_c5a7020c-ca8a-4389-bdf6-1d6ce18b63d0\\\">\\n <id?root=\\\"62edd24b-b963-41b8-ab35-510f34b821a5\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Emergence of New Psychotic or Manic Symptoms</paragraph>\\n <paragraph>Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania can be caused by stimulants at usual doses.\"\n },\n {\n \"VerbatimTerm\": \"hallucinations\",\n \"Probability\": \"0.9683688879\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n }\n ]\n },\n {\n \"Term\": \"hyperreflexia\",\n \"MEDDRACode\": \"10020745\",\n \"Overdose\": true,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"hyperreflexia\",\n \"Probability\": \"0.8232360482\",\n \"SemanticContext\": \"Symptoms Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rhabdomyolysis, rapid respiration, hyperpyrexia, confusion, assaultiveness, hallucinations, panic states.\"\n },\n {\n \"VerbatimTerm\": \"hyperreflexia\",\n \"Probability\": \"0.9853386879\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n }\n ]\n },\n {\n \"Term\": \"nausea\",\n \"MEDDRACode\": \"10028813\",\n \"Overdose\": true,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"nausea\",\n \"Probability\": \"0.9994989634\",\n \"SemanticContext\": \"Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps.\"\n },\n {\n \"VerbatimTerm\": \"nausea\",\n \"Probability\": \"0.9621075392\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n }\n ]\n },\n {\n \"Term\": \"vomiting\",\n \"MEDDRACode\": \"10047700\",\n \"Overdose\": true,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"vomiting\",\n \"Probability\": \"0.9995654821\",\n \"SemanticContext\": \"Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps.\"\n },\n {\n \"VerbatimTerm\": \"vomiting\",\n \"Probability\": \"0.9858412743\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n }\n ]\n },\n {\n \"Term\": \"pregnancy\",\n \"MEDDRACode\": \"10036556\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": true,\n \"Pregnancy\": true,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Pregnancy\",\n \"Probability\": \"0.0121068656\",\n \"SemanticContext\": \"Pregnancy\"\n },\n {\n \"VerbatimTerm\": \"Pregnancy\",\n \"Probability\": \"0.0125908256\",\n \"SemanticContext\": \"Pregnancy \\n <text>\\n <paragraph>Teratogenic Effects</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n <component>\\n <section?ID=\\\"LINK_9ebb2cfb-c8ce-4218-b627-02dfa98f1435\\\">\\n <id?root=\\\"daa4d052-ca6a-4013-97dc-503b97bf2a30\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Dextroamphetamine sulfate has been shown to have embryotoxic and teratogenic effects when administered to A/Jax mice and C57BL mice in doses approximately 41 times the maximum human dose.\"\n },\n {\n \"VerbatimTerm\": \"pregnant\",\n \"Probability\": \"0.0009802282\",\n \"SemanticContext\": \"There are no adequate and well-controlled studies in pregnant women.\"\n },\n {\n \"VerbatimTerm\": \"pregnancy\",\n \"Probability\": \"4.94404E-05\",\n \"SemanticContext\": \"Amphetamine sulfate tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.\"\n }\n ]\n },\n {\n \"Term\": \"aggression\",\n \"MEDDRACode\": \"10001488\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Aggressive behavior\",\n \"Probability\": \"0.4952290058\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_f4651d77-f40c-4521-8978-212a8266a211\\\">\\n <id?root=\\\"19a37e74-d56d-4be3-8728-0ca36865c042\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Aggression</paragraph>\\n <paragraph>Aggressive behavior or hostility is often observed in children and adolescents with ADHD, and has been reported in clinical trials and the postmarketing experience of some medications indicated for the treatment of ADHD.\"\n },\n {\n \"VerbatimTerm\": \"Aggression\",\n \"Probability\": \"0.5650114417\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_f4651d77-f40c-4521-8978-212a8266a211\\\">\\n <id?root=\\\"19a37e74-d56d-4be3-8728-0ca36865c042\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Aggression</paragraph>\\n <paragraph>Aggressive behavior or hostility is often observed in children and adolescents with ADHD, and has been reported in clinical trials and the postmarketing experience of some medications indicated for the treatment of ADHD.\"\n },\n {\n \"VerbatimTerm\": \"aggressive behavior\",\n \"Probability\": \"0.056851089\",\n \"SemanticContext\": \"Although there is no systematic evidence that stimulants cause aggressive behavior or hostility, patients beginning treatment for ADHD should be monitored for the appearance of or worsening of aggressive behavior or hostility.\"\n }\n ]\n },\n {\n \"Term\": \"autonomic nervous system imbalance\",\n \"MEDDRACode\": \"10003840\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"autonomic instability\",\n \"Probability\": \"0.8977234364\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n }\n ]\n },\n {\n \"Term\": \"bipolar disorder\",\n \"MEDDRACode\": \"10057667\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"bipolar disorder\",\n \"Probability\": \"9.23149E-05\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_48bbdf15-0d99-4bde-afb6-c20acefcb8cc\\\">\\n <id?root=\\\"f1101b74-266a-4642-9be5-d382b24dbd46\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Bipolar Illness</paragraph>\\n <paragraph>Particular care should be taken in using stimulants to treat ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/manic episode in such patients.\"\n },\n {\n \"VerbatimTerm\": \"bipolar disorder\",\n \"Probability\": \"0.0001152808\",\n \"SemanticContext\": \"Prior to initiating treatment with a stimulant, patients with comorbid depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.\"\n }\n ]\n },\n {\n \"Term\": \"blood pressure increased\",\n \"MEDDRACode\": \"10005750\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"increases in blood pressure\",\n \"Probability\": \"4.20819E-05\",\n \"SemanticContext\": \"Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate, e.g., those with pre-existing hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia \\n <content?styleCode=\\\"italics\\\">see </content>\\n <content?styleCode=\\\"bold\\\">\\n <linkHtml?href=\\\"#LINK_2f759a45-d082-4553-9ba5-71ca27a70c92\\\">CONTRAINDICATIONS</linkHtml>\\n </content> .\"\n }\n ]\n },\n {\n \"Term\": \"cardiac failure\",\n \"MEDDRACode\": \"10007554\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"heart failure\",\n \"Probability\": \"0.0074619055\",\n \"SemanticContext\": \"Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate, e.g., those with pre-existing hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia\\n <content?styleCode=\\\"italics\\\">see </content>\\n <content?styleCode=\\\"bold\\\">\\n <linkHtml?href=\\\"#LINK_2f759a45-d082-4553-9ba5-71ca27a70c92\\\">CONTRAINDICATIONS</linkHtml>\\n </content> .\"\n }\n ]\n },\n {\n \"Term\": \"cerebrovascular accident\",\n \"MEDDRACode\": \"10008190\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"stroke\",\n \"Probability\": \"0.7550399303\",\n \"SemanticContext\": \"\\n </paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_efa7df84-150a-4598-9695-25391cd4fe92\\\">\\n <id?root=\\\"62da430a-1692-4410-a818-cc566db86d8f\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>\\n <content?styleCode=\\\"italics\\\">Adults</content>\\n </paragraph>\\n <paragraph>Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD.\"\n }\n ]\n },\n {\n \"Term\": \"chest pain\",\n \"MEDDRACode\": \"10008479\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"exertional chest pain\",\n \"Probability\": \"0.0013147295\",\n \"SemanticContext\": \"Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during stimulant treatment should undergo a prompt cardiac evaluation.\"\n }\n ]\n },\n {\n \"Term\": \"coordination abnormal\",\n \"MEDDRACode\": \"10010947\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"incoordination\",\n \"Probability\": \"0.9714050889\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n }\n ]\n },\n {\n \"Term\": \"coronary artery disease\",\n \"MEDDRACode\": \"10011078\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"coronary artery disease\",\n \"Probability\": \"0.0619254112\",\n \"SemanticContext\": \"Although the role of stimulants in these adult cases is also unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems.\"\n }\n ]\n },\n {\n \"Term\": \"delirium\",\n \"MEDDRACode\": \"10012218\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"delirium\",\n \"Probability\": \"0.9912375212\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n }\n ]\n },\n {\n \"Term\": \"depressive symptom\",\n \"MEDDRACode\": \"10054089\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"depressive symptoms\",\n \"Probability\": \"1.77432E-05\",\n \"SemanticContext\": \"Prior to initiating treatment with a stimulant, patients with comorbid depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.\"\n }\n ]\n },\n {\n \"Term\": \"echocardiogram\",\n \"MEDDRACode\": \"10014113\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"echocardiogram\",\n \"Probability\": \"2.2153E-05\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_1fb30e55-bf8f-4e7d-a4e5-d8a599e04668\\\">\\n <id?root=\\\"74b99e07-0470-4b26-914b-8de521f757e6\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Assessing Cardiovascular Status in Patients Being Treated with Stimulant Medications</paragraph>\\n <paragraph>Children, adolescents, or adults who are being considered for treatment with stimulant medications should have a careful history including assessment for a family history of sudden death or ventricular arrhythmia and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease e.g., electrocardiogram and echocardiogram .\"\n }\n ]\n },\n {\n \"Term\": \"electrocardiogram\",\n \"MEDDRACode\": \"10014362\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"electrocardiogram\",\n \"Probability\": \"2.62324E-05\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_1fb30e55-bf8f-4e7d-a4e5-d8a599e04668\\\">\\n <id?root=\\\"74b99e07-0470-4b26-914b-8de521f757e6\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Assessing Cardiovascular Status in Patients Being Treated with Stimulant Medications</paragraph>\\n <paragraph>Children, adolescents, or adults who are being considered for treatment with stimulant medications should have a careful history including assessment for a family history of sudden death or ventricular arrhythmia and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease e.g., electrocardiogram and echocardiogram .\"\n }\n ]\n },\n {\n \"Term\": \"exercise adequate\",\n \"MEDDRACode\": \"10015636\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"exercised\",\n \"Probability\": \"5.73821E-05\",\n \"SemanticContext\": \"PRECAUTIONS General Caution is to be exercised in prescribing amphetamines for patients with even mild hypertension.\"\n }\n ]\n },\n {\n \"Term\": \"familial risk factor\",\n \"MEDDRACode\": \"10064117\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"family history of suicide\",\n \"Probability\": \"0.0006710291\",\n \"SemanticContext\": \"Prior to initiating treatment with a stimulant, patients with comorbid depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.\"\n }\n ]\n },\n {\n \"Term\": \"flatulence\",\n \"MEDDRACode\": \"10016766\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"wounds\",\n \"Probability\": \"6.2933E-06\",\n \"SemanticContext\": \"\\n </item>\\n <item>\\n <content?styleCode=\\\"bold\\\">Instruct patients to call their physician immediately with any signs of unexplained wounds appearing on fingers or toes while taking amphetamine sulfate tablets.\"\n }\n ]\n },\n {\n \"Term\": \"flushing\",\n \"MEDDRACode\": \"10016825\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"flushing\",\n \"Probability\": \"0.9765244722\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n }\n ]\n },\n {\n \"Term\": \"heart rate\",\n \"MEDDRACode\": \"10019299\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"heart rate\",\n \"Probability\": \"0.011277169\",\n \"SemanticContext\": \"\\n </paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_a8c33687-9be4-4bbe-b513-5ea06f35844b\\\">\\n <id?root=\\\"ae542c3e-c674-44f7-be43-483a5ae2fe56\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Hypertension and Other Cardiovascular Conditions</paragraph>\\n <paragraph>Stimulant medications cause a modest increase in average blood pressure about 2 to 4 mmHg and average heart rate about 3 to 6 bpm , and individuals may have larger increases.\"\n },\n {\n \"VerbatimTerm\": \"heart rate\",\n \"Probability\": \"0.0244780481\",\n \"SemanticContext\": \"While the mean changes alone would not be expected to have short-term consequences, all patients should be monitored for larger changes in heart rate and blood pressure.\"\n },\n {\n \"VerbatimTerm\": \"heart rate\",\n \"Probability\": \"9.2352E-06\",\n \"SemanticContext\": \"Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate, e.g., those with pre-existing hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia \\n <content?styleCode=\\\"italics\\\">see </content>\\n <content?styleCode=\\\"bold\\\">\\n <linkHtml?href=\\\"#LINK_2f759a45-d082-4553-9ba5-71ca27a70c92\\\">CONTRAINDICATIONS</linkHtml>\\n </content> .\"\n }\n ]\n },\n {\n \"Term\": \"hostility\",\n \"MEDDRACode\": \"10020400\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"hostility\",\n \"Probability\": \"0.1365937293\",\n \"SemanticContext\": \"\\n </paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_f4651d77-f40c-4521-8978-212a8266a211\\\">\\n <id?root=\\\"19a37e74-d56d-4be3-8728-0ca36865c042\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Aggression</paragraph>\\n <paragraph>Aggressive behavior or hostility is often observed in children and adolescents with ADHD, and has been reported in clinical trials and the postmarketing experience of some medications indicated for the treatment of ADHD.\"\n },\n {\n \"VerbatimTerm\": \"hostility\",\n \"Probability\": \"0.0142891109\",\n \"SemanticContext\": \"Although there is no systematic evidence that stimulants cause aggressive behavior or hostility, patients beginning treatment for ADHD should be monitored for the appearance of or worsening of aggressive behavior or hostility.\"\n }\n ]\n },\n {\n \"Term\": \"hyperhidrosis\",\n \"MEDDRACode\": \"10020642\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"diaphoresis\",\n \"Probability\": \"0.9664537907\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n }\n ]\n },\n {\n \"Term\": \"hyperthermia\",\n \"MEDDRACode\": \"10020843\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"hyperthermia\",\n \"Probability\": \"0.9822801352\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n }\n ]\n },\n {\n \"Term\": \"hypoaesthesia\",\n \"MEDDRACode\": \"10020937\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"numbness\",\n \"Probability\": \"0.0003771782\",\n \"SemanticContext\": \"\\n </item>\\n <item>Instruct patients to report to their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes.\"\n }\n ]\n },\n {\n \"Term\": \"illness\",\n \"MEDDRACode\": \"10080284\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Illness\",\n \"Probability\": \"0.0083942413\",\n \"SemanticContext\": \"\\n </paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_48bbdf15-0d99-4bde-afb6-c20acefcb8cc\\\">\\n <id?root=\\\"f1101b74-266a-4642-9be5-d382b24dbd46\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Bipolar Illness</paragraph>\\n <paragraph>Particular care should be taken in using stimulants to treat ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/manic episode in such patients.\"\n },\n {\n \"VerbatimTerm\": \"illness\",\n \"Probability\": \"0.0022287071\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_c5a7020c-ca8a-4389-bdf6-1d6ce18b63d0\\\">\\n <id?root=\\\"62edd24b-b963-41b8-ab35-510f34b821a5\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Emergence of New Psychotic or Manic Symptoms</paragraph>\\n <paragraph>Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania can be caused by stimulants at usual doses.\"\n }\n ]\n },\n {\n \"Term\": \"induction and maintenance of anaesthesia\",\n \"MEDDRACode\": \"10021723\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"induction\",\n \"Probability\": \"0.000119947\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_48bbdf15-0d99-4bde-afb6-c20acefcb8cc\\\">\\n <id?root=\\\"f1101b74-266a-4642-9be5-d382b24dbd46\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Bipolar Illness</paragraph>\\n <paragraph>Particular care should be taken in using stimulants to treat ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/manic episode in such patients.\"\n }\n ]\n },\n {\n \"Term\": \"infant\",\n \"MEDDRACode\": \"10021731\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Infants\",\n \"Probability\": \"0.0043774247\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_7ac38a51-b94e-4f52-9d33-e82f66656f34\\\">\\n <id?root=\\\"85889fa7-56ab-4d35-bb9b-2d661b5b280a\\\"?/>\\n <code?code=\\\"34078-6\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"NONTERATOGENIC?EFFECTS?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Nonteratogenic Effects</paragraph>\\n <paragraph>Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight.\"\n },\n {\n \"VerbatimTerm\": \"infants\",\n \"Probability\": \"0.1500080824\",\n \"SemanticContext\": \"Also, these infants may experience symptoms of withdrawal as demonstrated by dysphoria, including agitation, and significant lassitude.\"\n }\n ]\n },\n {\n \"Term\": \"labile blood pressure\",\n \"MEDDRACode\": \"10023533\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"labile blood pressure\",\n \"Probability\": \"0.6304214001\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n }\n ]\n },\n {\n \"Term\": \"low birth weight baby\",\n \"MEDDRACode\": \"10067508\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"low birth weight\",\n \"Probability\": \"0.0822819173\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n </section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_7ac38a51-b94e-4f52-9d33-e82f66656f34\\\">\\n <id?root=\\\"85889fa7-56ab-4d35-bb9b-2d661b5b280a\\\"?/>\\n <code?code=\\\"34078-6\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"NONTERATOGENIC?EFFECTS?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Nonteratogenic Effects</paragraph>\\n <paragraph>Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight.\"\n }\n ]\n },\n {\n \"Term\": \"mania\",\n \"MEDDRACode\": \"10026749\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"manic episode\",\n \"Probability\": \"0.0194260776\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_48bbdf15-0d99-4bde-afb6-c20acefcb8cc\\\">\\n <id?root=\\\"f1101b74-266a-4642-9be5-d382b24dbd46\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Bipolar Illness</paragraph>\\n <paragraph>Particular care should be taken in using stimulants to treat ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/manic episode in such patients.\"\n },\n {\n \"VerbatimTerm\": \"mania\",\n \"Probability\": \"0.2346282899\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_c5a7020c-ca8a-4389-bdf6-1d6ce18b63d0\\\">\\n <id?root=\\\"62edd24b-b963-41b8-ab35-510f34b821a5\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Emergence of New Psychotic or Manic Symptoms</paragraph>\\n <paragraph>Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania can be caused by stimulants at usual doses.\"\n }\n ]\n },\n {\n \"Term\": \"manic symptom\",\n \"MEDDRACode\": \"10084119\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Manic Symptoms\",\n \"Probability\": \"0.0442666113\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_c5a7020c-ca8a-4389-bdf6-1d6ce18b63d0\\\">\\n <id?root=\\\"62edd24b-b963-41b8-ab35-510f34b821a5\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Emergence of New Psychotic or Manic Symptoms</paragraph>\\n <paragraph>Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania can be caused by stimulants at usual doses.\"\n },\n {\n \"VerbatimTerm\": \"manic symptoms\",\n \"Probability\": \"0.2078823447\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_c5a7020c-ca8a-4389-bdf6-1d6ce18b63d0\\\">\\n <id?root=\\\"62edd24b-b963-41b8-ab35-510f34b821a5\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Emergence of New Psychotic or Manic Symptoms</paragraph>\\n <paragraph>Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania can be caused by stimulants at usual doses.\"\n }\n ]\n },\n {\n \"Term\": \"mental status changes\",\n \"MEDDRACode\": \"10048294\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"mental status changes\",\n \"Probability\": \"0.3743161559\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n }\n ]\n },\n {\n \"Term\": \"muscle rigidity\",\n \"MEDDRACode\": \"10028330\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"rigidity\",\n \"Probability\": \"0.981264472\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n }\n ]\n },\n {\n \"Term\": \"myocardial infarction\",\n \"MEDDRACode\": \"10028596\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"myocardial infarction\",\n \"Probability\": \"0.3652757406\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_efa7df84-150a-4598-9695-25391cd4fe92\\\">\\n <id?root=\\\"62da430a-1692-4410-a818-cc566db86d8f\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>\\n <content?styleCode=\\\"italics\\\">Adults</content>\\n </paragraph>\\n <paragraph>Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD.\"\n },\n {\n \"VerbatimTerm\": \"myocardial infarction\",\n \"Probability\": \"0.0091465116\",\n \"SemanticContext\": \"Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate, e.g., those with pre-existing hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia \\n <content?styleCode=\\\"italics\\\">see </content>\\n <content?styleCode=\\\"bold\\\">\\n <linkHtml?href=\\\"#LINK_2f759a45-d082-4553-9ba5-71ca27a70c92\\\">CONTRAINDICATIONS</linkHtml>\\n </content> .\"\n }\n ]\n },\n {\n \"Term\": \"myoclonus\",\n \"MEDDRACode\": \"10028622\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"myoclonus\",\n \"Probability\": \"0.9899895191\",\n \"SemanticContext\": \"Serotonin syndrome symptoms may include mental status changes e.g., agitation, hallucinations, delirium, and coma , autonomic instability e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia , neuromuscular symptoms e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination , seizures, and/or gastrointestinal symptoms e.g., nausea, vomiting, diarrhea .\"\n }\n ]\n },\n {\n \"Term\": \"overweight\",\n \"MEDDRACode\": \"10033307\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"weight over\",\n \"Probability\": \"0.0017070174\",\n \"SemanticContext\": \"\\n </paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n</component>\\n</section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_6fd66f82-1c94-42dd-be7a-b55d4bcc4059\\\">\\n <id?root=\\\"71cacc65-1f33-4908-8a9f-bf6ed58b6dfd\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title>Long-Term Suppression of Growth Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated children over 36 months to the ages of 10 to 13 years , suggests that consistently medicated children i.e., treatment for 7 days per week throughout the year have a temporary slowing in growth rate on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years , without evidence of growth rebound during this period of development.\"\n }\n ]\n },\n {\n \"Term\": \"pain\",\n \"MEDDRACode\": \"10033371\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"pain\",\n \"Probability\": \"0.0007091165\",\n \"SemanticContext\": \"\\n </item>\\n <item>Instruct patients to report to their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes.\"\n }\n ]\n },\n {\n \"Term\": \"pallor\",\n \"MEDDRACode\": \"10033546\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"pale\",\n \"Probability\": \"0.0227641761\",\n \"SemanticContext\": \"\\n <text>\\n <paragraph>Circulation problems in fingers and toes [Peripheral vasculopathy, including Raynaud's phenomenon]</paragraph>\\n <list?listType=\\\"unordered\\\"?styleCode=\\\"Disk\\\">\\n <item>Instruct patients beginning treatment with amphetamine sulfate tablets about the risk of peripheral vasculopathy, including Raynaud's phenomenon, and associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change color from pale, to blue, to red.\"\n }\n ]\n },\n {\n \"Term\": \"premature delivery\",\n \"MEDDRACode\": \"10036595\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"premature delivery\",\n \"Probability\": \"0.5226562619\",\n \"SemanticContext\": \"\\n </paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n </section>\\n</component>\\n<component>\\n <section?ID=\\\"LINK_7ac38a51-b94e-4f52-9d33-e82f66656f34\\\">\\n <id?root=\\\"85889fa7-56ab-4d35-bb9b-2d661b5b280a\\\"?/>\\n <code?code=\\\"34078-6\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"NONTERATOGENIC?EFFECTS?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Nonteratogenic Effects</paragraph>\\n <paragraph>Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight.\"\n }\n ]\n },\n {\n \"Term\": \"raynaud's phenomenon\",\n \"MEDDRACode\": \"10037912\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Raynaud's Phenomenon\",\n \"Probability\": \"0.0106298327\",\n \"SemanticContext\": \"Peripheral Vasculopathy, Including Raynaud's Phenomenon Stimulants, including amphetamine sulfate tablets, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon.\"\n },\n {\n \"VerbatimTerm\": \"Raynaud's phenomenon\",\n \"Probability\": \"0.1435062885\",\n \"SemanticContext\": \"Peripheral Vasculopathy, Including Raynaud's Phenomenon Stimulants, including amphetamine sulfate tablets, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon.\"\n },\n {\n \"VerbatimTerm\": \"Raynaud's phenomenon\",\n \"Probability\": \"0.457239598\",\n \"SemanticContext\": \"Effects of peripheral vasculopathy, including Raynaud's phenomenon, were observed in post-marketing reports at different times and at therapeutic doses in all age groups throughout the course of treatment.\"\n },\n {\n \"VerbatimTerm\": \"Raynaud's phenomenon\",\n \"Probability\": \"0.2519610524\",\n \"SemanticContext\": \"\\n <text>\\n <paragraph>Circulation problems in fingers and toes [Peripheral vasculopathy, including Raynaud's phenomenon]</paragraph>\\n <list?listType=\\\"unordered\\\"?styleCode=\\\"Disk\\\">\\n <item>Instruct patients beginning treatment with amphetamine sulfate tablets about the risk of peripheral vasculopathy, including Raynaud's phenomenon, and associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change color from pale, to blue, to red.\"\n }\n ]\n },\n {\n \"Term\": \"skin discolouration\",\n \"MEDDRACode\": \"10040829\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"skin color\",\n \"Probability\": \"0.0005188584\",\n \"SemanticContext\": \"</item>\\n <item>Instruct patients to report to their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes.\"\n }\n ]\n },\n {\n \"Term\": \"sympathomimetic effect\",\n \"MEDDRACode\": \"10062119\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"sympathomimetic effects\",\n \"Probability\": \"0.0164240897\",\n \"SemanticContext\": \"Although some serious heart problems alone carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug \\n <content?styleCode=\\\"italics\\\">see </content>\\n <content?styleCode=\\\"bold\\\">\\n <linkHtml?href=\\\"#LINK_2f759a45-d082-4553-9ba5-71ca27a70c92\\\">CONTRAINDICATIONS</linkHtml>\\n </content> .\"\n }\n ]\n },\n {\n \"Term\": \"symptomatic treatment\",\n \"MEDDRACode\": \"10083815\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"symptomatic treatment\",\n \"Probability\": \"4.2515E-06\",\n \"SemanticContext\": \"Discontinue treatment with amphetamine sulfate tablets and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment.\"\n }\n ]\n },\n {\n \"Term\": \"syncope\",\n \"MEDDRACode\": \"10042772\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"syncope\",\n \"Probability\": \"0.0006890893\",\n \"SemanticContext\": \"Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during stimulant treatment should undergo a prompt cardiac evaluation.\"\n }\n ]\n },\n {\n \"Term\": \"ulcer\",\n \"MEDDRACode\": \"10045285\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"ulceration\",\n \"Probability\": \"0.3044728637\",\n \"SemanticContext\": \"Signs and symptoms are usually intermittent and mild; however, very rare sequelae include digital ulceration and/or soft tissue breakdown.\"\n }\n ]\n },\n {\n \"Term\": \"ventricular arrhythmia\",\n \"MEDDRACode\": \"10047281\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"ventricular arrhythmia\",\n \"Probability\": \"0.0004282892\",\n \"SemanticContext\": \"Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate, e.g., those with pre-existing hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia\\n <content?styleCode=\\\"italics\\\">see </content>\\n <content?styleCode=\\\"bold\\\">\\n <linkHtml?href=\\\"#LINK_2f759a45-d082-4553-9ba5-71ca27a70c92\\\">CONTRAINDICATIONS</linkHtml>\\n </content> .\"\n },\n {\n \"VerbatimTerm\": \"ventricular arrhythmia\",\n \"Probability\": \"0.0002111197\",\n \"SemanticContext\": \"\\n </paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_1fb30e55-bf8f-4e7d-a4e5-d8a599e04668\\\">\\n <id?root=\\\"74b99e07-0470-4b26-914b-8de521f757e6\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title?/>\\n <text>\\n <paragraph>Assessing Cardiovascular Status in Patients Being Treated with Stimulant Medications</paragraph>\\n <paragraph>Children, adolescents, or adults who are being considered for treatment with stimulant medications should have a careful history including assessment for a family history of sudden death or ventricular arrhythmia and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease e.g., electrocardiogram and echocardiogram .\"\n }\n ]\n },\n {\n \"Term\": \"vision blurred\",\n \"MEDDRACode\": \"10047513\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"blurring of vision\",\n \"Probability\": \"0.0105391741\",\n \"SemanticContext\": \"Visual Disturbance Difficulties with accommodation and blurring of vision have been reported with stimulant treatment.\"\n }\n ]\n },\n {\n \"Term\": \"visual impairment\",\n \"MEDDRACode\": \"10047571\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": false,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": false,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"Visual Disturbance\",\n \"Probability\": \"0.1412431002\",\n \"SemanticContext\": \"Visual Disturbance Difficulties with accommodation and blurring of vision have been reported with stimulant treatment.\"\n }\n ]\n },\n {\n \"Term\": \"acute stress disorder\",\n \"MEDDRACode\": \"10001084\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": true,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": true,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"acute stress reactions\",\n \"Probability\": \"0.0022159517\",\n \"SemanticContext\": \"When these symptoms are associated with acute stress reactions, treatment with amphetamines is usually not indicated.\"\n }\n ]\n },\n {\n \"Term\": \"thinking abnormal\",\n \"MEDDRACode\": \"10043431\",\n \"Overdose\": false,\n \"Warnings\": true,\n \"BoxedWarning\": false,\n \"AdverseReactions\": false,\n \"Contraindications\": false,\n \"DrugInteractions\": false,\n \"UseInSpecificPopulations\": {\n \"AnySection\": true,\n \"Pregnancy\": false,\n \"NursingMothers\": false,\n \"Lactation\": false,\n \"PediatricUse\": true,\n \"GeriatricUse\": false\n },\n \"Other\": false,\n \"Blacklisted\": false,\n \"Annotations\": [\n {\n \"VerbatimTerm\": \"thought disorder\",\n \"Probability\": \"0.5592387915\",\n \"SemanticContext\": \"</paragraph>\\n </text>\\n <effectiveTime?value=\\\"20220228\\\"?/>\\n </section>\\n </component>\\n </section>\\n </component>\\n <component>\\n <section?ID=\\\"LINK_f28bfe4d-6b1f-407e-8d65-44f84f42ab56\\\">\\n <id?root=\\\"51243722-0c1b-4804-87e7-742294dd22fd\\\"?/>\\n <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n <title>Psychiatric Adverse Events \\n <text>\\n <paragraph>Pre-Existing Psychosis</paragraph>\\n <paragraph>Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.\"\n },\n {\n \"VerbatimTerm\": \"thought disorder\",\n \"Probability\": \"0.4355452955\",\n \"SemanticContext\": \"Clinical experience suggests that in psychotic children, administration of amphetamines may exacerbate symptoms of behavior disturbance and thought disorder.\"\n }\n ]\n }\n ],\n \"IndicationTerms\": []\n}"}],"_postman_id":"46a1aa60-cd4d-4b7b-8cab-bf2c9ca82c8b"},{"name":"Label metadata for given date range","id":"57c1f8ca-56b8-42ad-9e89-b5a6d8da2ff7","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"auth":{"type":"basic","basic":{"basicConfig":[{"key":"username","value":"<username>"},{"key":"password","value":"<password>"}]},"isInherited":false},"method":"POST","header":[],"body":{"mode":"formdata","formdata":[{"key":"filtertype","value":"date","type":"text","description":"<p>Option is \"date\" (string)</p>\n"},{"key":"filtervalue","value":"20230315-20230321","type":"text","description":"<p>Option is date range as YYYYMMDD-YYYYMMDD (string)</p>\n"},{"key":"skip","value":"10","description":"<p>Value for Number of records to skip (integer). Defaults to 0</p>\n","type":"text"},{"key":"limit","value":"10","description":"<p>Value for number of records to fetch (integer). Defaults to 100</p>\n","type":"text"},{"key":"country","value":"all","description":"<p>Options are \"us\", \"uk\", \"ca\", \"eu\", \"au\", \"all\" (string). Defaults to \"us\"</p>\n","type":"text"}]},"url":"https://labelae.doctorevidence.com/V2/annotation/label","description":"<ul>\n<li>Returns labels metadata for all product labels that have been imported/updated between the given date range. Dates are stored in UTC and results are fetched as per UTC time. Time defaults to 00:00 and cannot be changed.</li>\n<li>This will return a maximum of 100 annotation details.</li>\n</ul>\n<p><strong>Note: All the Params should be passed as raw data in JSON format (</strong> eg. { \"skip\":0, \"limit\":10 } <strong>)</strong></p>\n","urlObject":{"protocol":"https","path":["V2","annotation","label"],"host":["labelae","doctorevidence","com"],"query":[],"variable":[]}},"response":[{"id":"0c7c7f72-fd5c-42ef-84c6-3cc40c75b388","name":"Label metadata for given date range","originalRequest":{"method":"POST","header":[{"key":"Content-Type","value":"application/json"}],"body":{"mode":"raw","raw":"{\n \"filtertype\": \"date\",\n \"filtervalue\": \"20230315-20230321\",\n \"skip\": 10,\n \"limit\": 10,\n \"country\": \"all\"\n}","options":{"raw":{"language":"json"}}},"url":"https://labelae.doctorevidence.com/V2/annotation/label"},"status":"OK","code":200,"_postman_previewlanguage":"json","header":[{"key":"Content-Encoding","value":"gzip"},{"key":"Content-Type","value":"text/plain; charset=utf-8"},{"key":"Date","value":"Mon, 29 Apr 2024 06:27:25 GMT"},{"key":"Server","value":"Kestrel"},{"key":"Vary","value":"Accept-Encoding"},{"key":"Transfer-Encoding","value":"chunked"}],"cookie":[],"responseTime":null,"body":"{\n \"current\": 119,\n \"archived\": 0,\n \"totalcount\": 119,\n \"alllabels\": [\n {\n \"Country\": \"AU\",\n \"TotalLabels\": 7467,\n \"TotalActive\": 7467,\n \"TotalArchived\": 0\n },\n {\n \"Country\": \"UK\",\n \"TotalLabels\": 9769,\n \"TotalActive\": 9769,\n \"TotalArchived\": 0\n },\n {\n \"Country\": \"EU\",\n \"TotalLabels\": 2061,\n \"TotalActive\": 2061,\n \"TotalArchived\": 0\n },\n {\n \"Country\": \"CA\",\n \"TotalLabels\": 11493,\n \"TotalActive\": 11493,\n \"TotalArchived\": 0\n },\n {\n \"Country\": \"US\",\n \"TotalLabels\": 14388,\n \"TotalActive\": 14388,\n \"TotalArchived\": 0\n }\n ],\n \"skip\": 10,\n \"limit\": 10,\n \"BaseURL\": \"https://labelae.doctorevidence.com/V2/annotation/label/\",\n \"MeddraVersion\": \"26.1\",\n \"data\": [\n {\n \"GenericName\": \"cycloserine\",\n \"Labels\": [\n {\n \"Id\": \"USf87588c1-1380-ddad-0927-954cfad15ded\",\n \"NDCCode\": \"43598-235\",\n \"UpdatedDate\": \"Mar 16, 2023\",\n \"LabelSource\": {\n \"LabelTitle\": \"CYCLOSERINE - cycloserine capsule Dr. Reddy’s Laboratories, Inc.\",\n \"TradeName\": \"Cycloserine\",\n \"Manufacturer\": \"Dr. Reddy?s Laboratories, Inc.\",\n \"Country\": \"us\",\n \"ProductId\": \"8e7e2665-7a3d-3f54-9f92-5fe845f02ef9\",\n \"FileId\": \"f87588c1-1380-ddad-0927-954cfad15ded\",\n \"Version\": \"1\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e7e2665-7a3d-3f54-9f92-5fe845f02ef9\",\n \"genericNames\": \"cycloserine\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"budesonide\",\n \"Labels\": [\n {\n \"Id\": \"US2992bea0-f907-4768-a6ba-7fb39b7d8ad5\",\n \"NDCCode\": \"55566-1002\",\n \"UpdatedDate\": \"Mar 16, 2023\",\n \"LabelSource\": {\n \"LabelTitle\": \"ORTIKOS - budesonide capsule Ferring Pharmaceuticals Inc.\",\n \"TradeName\": \"Ortikos\",\n \"Manufacturer\": \"Ferring Pharmaceuticals Inc.\",\n \"Country\": \"us\",\n \"ProductId\": \"0b675429-878d-496e-85af-9e46201a10ea\",\n \"FileId\": \"2992bea0-f907-4768-a6ba-7fb39b7d8ad5\",\n \"Version\": \"8\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b675429-878d-496e-85af-9e46201a10ea\",\n \"genericNames\": \"budesonide\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"mexiletine hydrochloride\",\n \"Labels\": [\n {\n \"Id\": \"USc142344e-c6b9-47b6-90aa-57a0686a40ed\",\n \"NDCCode\": \"62559-820\",\n \"UpdatedDate\": \"Mar 16, 2023\",\n \"LabelSource\": {\n \"LabelTitle\": \"MEXILETINE HYDROCHLORIDE - mexiletine hydrochloride capsule ANI Pharmaceuticals, Inc.\",\n \"TradeName\": \"Mexiletine Hydrochloride\",\n \"Manufacturer\": \"ANI Pharmaceuticals, Inc.\",\n \"Country\": \"us\",\n \"ProductId\": \"1b3a807f-368a-42dc-8266-ddf8347a8826\",\n \"FileId\": \"c142344e-c6b9-47b6-90aa-57a0686a40ed\",\n \"Version\": \"3\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b3a807f-368a-42dc-8266-ddf8347a8826\",\n \"genericNames\": \"mexiletine hydrochloride\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"thiamine hydrochloride\",\n \"Labels\": [\n {\n \"Id\": \"US8909424c-9d5b-4e35-b2d3-da9d3316a4cc\",\n \"NDCCode\": \"65145-129\",\n \"UpdatedDate\": \"Mar 16, 2023\",\n \"LabelSource\": {\n \"LabelTitle\": \"THIAMINE  - thiamine hydrochloride injection, solution Caplin Steriles Limited\",\n \"TradeName\": \"Thiamine\",\n \"Manufacturer\": \"Caplin Steriles Limited\",\n \"Country\": \"us\",\n \"ProductId\": \"8909424c-9d5b-4e35-b2d3-da9d3316a4cc\",\n \"FileId\": \"8909424c-9d5b-4e35-b2d3-da9d3316a4cc\",\n \"Version\": \"1\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8909424c-9d5b-4e35-b2d3-da9d3316a4cc\",\n \"genericNames\": \"thiamine hydrochloride\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"epinastine hydrochloride\",\n \"Labels\": [\n {\n \"Id\": \"US6917c9f5-a785-4ba2-86a2-dfbc6852d839\",\n \"NDCCode\": \"51991-836\",\n \"UpdatedDate\": \"Mar 16, 2023\",\n \"LabelSource\": {\n \"LabelTitle\": \"EPINASTINE HYDROCHLORIDE - epinastine hydrochloride solution/ drops Breckenridge Pharmaceutical, Inc.\",\n \"TradeName\": \"Epinastine Hydrochloride\",\n \"Manufacturer\": \"Breckenridge Pharmaceutical, Inc.\",\n \"Country\": \"us\",\n \"ProductId\": \"8ff37968-22a1-4904-a139-977463790f12\",\n \"FileId\": \"6917c9f5-a785-4ba2-86a2-dfbc6852d839\",\n \"Version\": \"11\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ff37968-22a1-4904-a139-977463790f12\",\n \"genericNames\": \"epinastine hydrochloride\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"prazosin hydrochloride\",\n \"Labels\": [\n {\n \"Id\": \"USfea187a3-ee8b-4463-8485-3b1de1504609\",\n \"NDCCode\": \"46708-691\",\n \"UpdatedDate\": \"Mar 16, 2023\",\n \"LabelSource\": {\n \"LabelTitle\": \"PRAZOSIN HYDROCHLORIDE  - prazosin hydrochloride capsule Alembic Pharmaceuticals Limited\",\n \"TradeName\": \"PRAZOSIN HYDROCHLORIDE\",\n \"Manufacturer\": \"Alembic Pharmaceuticals Limited\",\n \"Country\": \"us\",\n \"ProductId\": \"fea187a3-ee8b-4463-8485-3b1de1504609\",\n \"FileId\": \"fea187a3-ee8b-4463-8485-3b1de1504609\",\n \"Version\": \"1\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fea187a3-ee8b-4463-8485-3b1de1504609\",\n \"genericNames\": \"prazosin hydrochloride\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"calcium acetate\",\n \"Labels\": [\n {\n \"Id\": \"US7749772b-1a26-4b2e-b97d-3ee29611d035\",\n \"NDCCode\": \"69097-862\",\n \"UpdatedDate\": \"Mar 17, 2023\",\n \"LabelSource\": {\n \"LabelTitle\": \"CALCIUM ACETATE - calcium acetate capsule Cipla USA Inc.,\",\n \"TradeName\": \"Calcium Acetate\",\n \"Manufacturer\": \"Cipla USA Inc.,\",\n \"Country\": \"us\",\n \"ProductId\": \"000c044a-12ef-4484-942e-99552b777d58\",\n \"FileId\": \"7749772b-1a26-4b2e-b97d-3ee29611d035\",\n \"Version\": \"6\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=000c044a-12ef-4484-942e-99552b777d58\",\n \"genericNames\": \"calcium acetate\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"insulin aspart\",\n \"Labels\": [\n {\n \"Id\": \"USec67820c-4008-4894-b933-34b28704221d\",\n \"NDCCode\": \"73070-200\",\n \"UpdatedDate\": \"Mar 16, 2023\",\n \"LabelSource\": {\n \"LabelTitle\": \"INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30 - insulin aspart injection, suspension Novo Nordisk Pharma, Inc.\",\n \"TradeName\": \"Insulin Aspart Protamine and Insulin Aspart\",\n \"Manufacturer\": \"Novo Nordisk Pharma, Inc.\",\n \"Country\": \"us\",\n \"ProductId\": \"fc94baa4-3606-48bc-a781-9617ab6960ef\",\n \"FileId\": \"ec67820c-4008-4894-b933-34b28704221d\",\n \"Version\": \"7\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc94baa4-3606-48bc-a781-9617ab6960ef\",\n \"genericNames\": \"insulin aspart\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"cyanocobalamin\",\n \"Labels\": [\n {\n \"Id\": \"USb1dd7657-05bd-4062-89f1-9e11f0042f3e\",\n \"NDCCode\": \"25021-502\",\n \"UpdatedDate\": \"Mar 16, 2023\",\n \"LabelSource\": {\n \"LabelTitle\": \"CYANOCOBALAMIN - cyanocobalamin injection, solution Sagent Pharmaceuticals\",\n \"TradeName\": \"Cyanocobalamin\",\n \"Manufacturer\": \"Sagent Pharmaceuticals\",\n \"Country\": \"us\",\n \"ProductId\": \"7e10c47d-1036-47c1-a0ed-6929636366c2\",\n \"FileId\": \"b1dd7657-05bd-4062-89f1-9e11f0042f3e\",\n \"Version\": \"4\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e10c47d-1036-47c1-a0ed-6929636366c2\",\n \"genericNames\": \"cyanocobalamin\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"rocuronium bromide\",\n \"Labels\": [\n {\n \"Id\": \"US8a5dbb63-22bd-4bb5-9b7e-3a95792c89a9\",\n \"NDCCode\": \"65145-130\",\n \"UpdatedDate\": \"Mar 16, 2023\",\n \"LabelSource\": {\n \"LabelTitle\": \"ROCURONIUM BROMIDE  - rocuronium bromide injection, solution Caplin Steriles Limited\",\n \"TradeName\": \"ROCURONIUM BROMIDE\",\n \"Manufacturer\": \"Caplin Steriles Limited\",\n \"Country\": \"us\",\n \"ProductId\": \"f1794318-b058-4254-97b7-d4e07126efbb\",\n \"FileId\": \"8a5dbb63-22bd-4bb5-9b7e-3a95792c89a9\",\n \"Version\": \"3\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1794318-b058-4254-97b7-d4e07126efbb\",\n \"genericNames\": \"rocuronium bromide\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n }\n ]\n}"}],"_postman_id":"57c1f8ca-56b8-42ad-9e89-b5a6d8da2ff7"},{"name":"Label metadata for given generic names","id":"d3d6b6ed-c1ab-4753-968e-f0c527fc6928","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"auth":{"type":"basic","basic":{"basicConfig":[{"key":"username","value":"<username>"},{"key":"password","value":"<password>"}]},"isInherited":false},"method":"POST","header":[],"body":{"mode":"formdata","formdata":[{"key":"filtertype","value":"genericname","type":"text","description":"<p>Option is \"genericname\" (string)</p>\n"},{"key":"filtervalue","value":"Allopurinol sodium;aflibercept;Alfuzosin\nHCl;AMANTADINE HYDROCHLORIDE;anagrelide;andexanet alfa;Albuterol Sulfate;Amiodarone Hydrochloride","type":"text","description":"<p>Option is semi-colon separated genericnames (string)</p>\n"},{"key":"skip","value":"0","type":"text","description":"<p>Value for Number of records to skip (integer). Defaults to 0</p>\n"},{"key":"limit","value":"10","type":"text","description":"<p>Value for number of records to fetch (integer). Defaults to 100</p>\n"},{"key":"country","value":"all","description":"<p>Options are \"us\", \"uk\", \"ca\", \"eu\", \"au\", \"all\" (string). Defaults to \"us\"</p>\n","type":"text"},{"key":"","value":"","type":"text","disabled":true}]},"url":"https://labelae.doctorevidence.com/v2/annotation/label","description":"<ul>\n<li>Returns label metadata matching a given set of generic names.</li>\n<li>User can pass generic names retrieved from endpoint \"<a href=\"#650bd5aa-57c3-4301-91fc-3b50621b259a\">annotation/genericnames</a>\", as up to a 100 semi-colon separated values .</li>\n<li>Multiple generic names are treated as \"OR\" queries.</li>\n<li>This will return a maximum of 100 annotation details.</li>\n</ul>\n<p><strong>Note: All the Params should be passed as raw data in JSON format (</strong> eg. { \"skip\":0, \"limit\":10 } <strong>)</strong></p>\n","urlObject":{"protocol":"https","path":["v2","annotation","label"],"host":["labelae","doctorevidence","com"],"query":[],"variable":[]}},"response":[{"id":"33f19051-c5ae-4fc6-902f-12bd1a57c733","name":"Label metadata for given generic names","originalRequest":{"method":"POST","header":[{"key":"Content-Type","value":"application/json"}],"body":{"mode":"raw","raw":"{\n \"filtertype\": \"genericname\",\n \"filtervalue\": \"Allopurinol sodium;aflibercept;Alfuzosin HCl;AMANTADINE HYDROCHLORIDE;anagrelide;andexanet alfa;Albuterol Sulfate;Amiodarone Hydrochloride\",\n \"skip\": 0,\n \"limit\": 10,\n \"country\": \"all\"\n}","options":{"raw":{"language":"json"}}},"url":"https://labelae.doctorevidence.com/v2/annotation/label"},"status":"OK","code":200,"_postman_previewlanguage":"json","header":[{"key":"Content-Encoding","value":"gzip"},{"key":"Content-Type","value":"text/plain; charset=utf-8"},{"key":"Date","value":"Mon, 29 Apr 2024 06:32:23 GMT"},{"key":"Server","value":"Kestrel"},{"key":"Vary","value":"Accept-Encoding"},{"key":"Transfer-Encoding","value":"chunked"}],"cookie":[],"responseTime":null,"body":"{\n \"current\": 142,\n \"archived\": 0,\n \"totalcount\": 142,\n \"alllabels\": [\n {\n \"Country\": \"AU\",\n \"TotalLabels\": 7467,\n \"TotalActive\": 7467,\n \"TotalArchived\": 0\n },\n {\n \"Country\": \"UK\",\n \"TotalLabels\": 9769,\n \"TotalActive\": 9769,\n \"TotalArchived\": 0\n },\n {\n \"Country\": \"EU\",\n \"TotalLabels\": 2061,\n \"TotalActive\": 2061,\n \"TotalArchived\": 0\n },\n {\n \"Country\": \"CA\",\n \"TotalLabels\": 11493,\n \"TotalActive\": 11493,\n \"TotalArchived\": 0\n },\n {\n \"Country\": \"US\",\n \"TotalLabels\": 14388,\n \"TotalActive\": 14388,\n \"TotalArchived\": 0\n }\n ],\n \"skip\": 0,\n \"limit\": 10,\n \"BaseURL\": \"https://labelae.doctorevidence.com/V2/annotation/label/\",\n \"MeddraVersion\": \"26.1\",\n \"data\": [\n {\n \"GenericName\": \"albuterol sulfate\",\n \"Labels\": [\n {\n \"Id\": \"US87747f82-9009-ab34-e053-2995a90a6808\",\n \"NDCCode\": \"76519-1175\",\n \"UpdatedDate\": \"May 02, 2019\",\n \"LabelSource\": {\n \"LabelTitle\": \"ALBUTEROL SULFATE HFA - albuterol sulfate aerosol, metered H.J. Harkins Company, Inc.\",\n \"TradeName\": \"ALBUTEROL SULFATE\",\n \"Manufacturer\": \"H.J. Harkins Company, Inc.\",\n \"Country\": \"us\",\n \"ProductId\": \"87747f82-9008-ab34-e053-2995a90a6808\",\n \"FileId\": \"87747f82-9009-ab34-e053-2995a90a6808\",\n \"Version\": \"1\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87747f82-9008-ab34-e053-2995a90a6808\",\n \"genericNames\": \"albuterol sulfate\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n },\n {\n \"Id\": \"US874bcb9b-3b52-1375-e053-2a95a90ad559\",\n \"NDCCode\": \"76519-1171\",\n \"UpdatedDate\": \"Apr 26, 2019\",\n \"LabelSource\": {\n \"LabelTitle\": \"ALBUTEROL SULFATE HFA - albuterol sulfate aerosol, metered H.J. Harkins Company, Inc.\",\n \"TradeName\": \"ALBUTEROL SULFATE\",\n \"Manufacturer\": \"H.J. Harkins Company, Inc.\",\n \"Country\": \"us\",\n \"ProductId\": \"874bcb9b-3b51-1375-e053-2a95a90ad559\",\n \"FileId\": \"874bcb9b-3b52-1375-e053-2a95a90ad559\",\n \"Version\": \"1\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=874bcb9b-3b51-1375-e053-2a95a90ad559\",\n \"genericNames\": \"albuterol sulfate\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n },\n {\n \"Id\": \"US9871f5f3-a434-4258-a866-0234d96b6f89\",\n \"NDCCode\": \"0085-1132\",\n \"UpdatedDate\": \"Oct 09, 2019\",\n \"LabelSource\": {\n \"LabelTitle\": \"PROVENTIL HFA - albuterol sulfate aerosol, metered Merck Sharp & Dohme Corp.\",\n \"TradeName\": \"Proventil HFA\",\n \"Manufacturer\": \"Merck Sharp & Dohme Corp.\",\n \"Country\": \"us\",\n \"ProductId\": \"f454947c-6055-474b-bf35-29a379e01aa3\",\n \"FileId\": \"9871f5f3-a434-4258-a866-0234d96b6f89\",\n \"Version\": \"17\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f454947c-6055-474b-bf35-29a379e01aa3\",\n \"genericNames\": \"albuterol sulfate\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n },\n {\n \"Id\": \"USbd0c8367-59b1-60be-e053-2995a90a6b85\",\n \"NDCCode\": \"0254-1007\",\n \"UpdatedDate\": \"Mar 11, 2021\",\n \"LabelSource\": {\n \"LabelTitle\": \"ALBUTEROL SULFATE - albuterol sulfate aerosol, metered Par Pharmaceutical Inc.\",\n \"TradeName\": \"Albuterol Sulfate\",\n \"Manufacturer\": \"Par Pharmaceutical Inc.\",\n \"Country\": \"us\",\n \"ProductId\": \"498c7eff-645b-4a79-be12-afe9dbd5f3c4\",\n \"FileId\": \"bd0c8367-59b1-60be-e053-2995a90a6b85\",\n \"Version\": \"5\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=498c7eff-645b-4a79-be12-afe9dbd5f3c4\",\n \"genericNames\": \"albuterol sulfate\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n },\n {\n \"Id\": \"US7733f37e-01bb-48d6-96fc-bbb95dc27307\",\n \"NDCCode\": \"0378-0255\",\n \"UpdatedDate\": \"Sep 17, 2021\",\n \"LabelSource\": {\n \"LabelTitle\": \"ALBUTEROL - albuterol sulfate tablet Mylan Pharmaceuticals Inc.\",\n \"TradeName\": \"Albuterol\",\n \"Manufacturer\": \"Mylan Pharmaceuticals Inc.\",\n \"Country\": \"us\",\n \"ProductId\": \"1c1f3881-2b68-4bdb-a12f-8134fe8ba961\",\n \"FileId\": \"7733f37e-01bb-48d6-96fc-bbb95dc27307\",\n \"Version\": \"11\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c1f3881-2b68-4bdb-a12f-8134fe8ba961\",\n \"genericNames\": \"albuterol sulfate\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n },\n {\n \"Id\": \"USd129e8b6-6957-7b79-e053-2995a90a94e2\",\n \"NDCCode\": \"0472-0825\",\n \"UpdatedDate\": \"Nov 23, 2021\",\n \"LabelSource\": {\n \"LabelTitle\": \"ALBUTEROL SULFATE - albuterol sulfate syrup Actavis Pharma, Inc.\",\n \"TradeName\": \"Albuterol Sulfate\",\n \"Manufacturer\": \"Actavis Pharma, Inc.\",\n \"Country\": \"us\",\n \"ProductId\": \"8bac1efe-c419-a615-fab5-0770b0ce90d9\",\n \"FileId\": \"d129e8b6-6957-7b79-e053-2995a90a94e2\",\n \"Version\": \"7\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bac1efe-c419-a615-fab5-0770b0ce90d9\",\n \"genericNames\": \"albuterol sulfate\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"alfuzosin hcl\",\n \"Labels\": [\n {\n \"Id\": \"US9f852c9b-350d-4d1a-a54a-85151ccad544\",\n \"NDCCode\": \"59212-200\",\n \"UpdatedDate\": \"Aug 26, 2021\",\n \"LabelSource\": {\n \"LabelTitle\": \"UROXATRAL  - alfuzosin hydrochloride tablet, extended release Concordia Pharmaceuticals Inc.\",\n \"TradeName\": \"Uroxatral\",\n \"Manufacturer\": \"Concordia Pharmaceuticals Inc.\",\n \"Country\": \"us\",\n \"ProductId\": \"9fc7f119-f36b-44cf-945d-940160f3afe3\",\n \"FileId\": \"9f852c9b-350d-4d1a-a54a-85151ccad544\",\n \"Version\": \"8\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9fc7f119-f36b-44cf-945d-940160f3afe3\",\n \"genericNames\": \"alfuzosin hcl\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"amiodarone hydrochloride\",\n \"Labels\": [\n {\n \"Id\": \"US2c1bc6a8-20ff-483a-ae28-fb31fa5f684a\",\n \"NDCCode\": \"68083-112\",\n \"UpdatedDate\": \"Aug 28, 2021\",\n \"LabelSource\": {\n \"LabelTitle\": \"AMIODARONE HYDROCHLORIDE  - amiodarone hydrochloride injection, solution Gland Pharma Limited\",\n \"TradeName\": \"Amiodarone hydrochloride\",\n \"Manufacturer\": \"GLAND PHARMA LTD\",\n \"Country\": \"us\",\n \"ProductId\": \"1f00c333-9667-4ebc-8849-009a3779c0c9\",\n \"FileId\": \"2c1bc6a8-20ff-483a-ae28-fb31fa5f684a\",\n \"Version\": \"5\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f00c333-9667-4ebc-8849-009a3779c0c9\",\n \"genericNames\": \"amiodarone hydrochloride\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n },\n {\n \"GenericName\": \"amantadine hydrochloride\",\n \"Labels\": [\n {\n \"Id\": \"USd124ff30-7360-4446-e053-2995a90af5ff\",\n \"NDCCode\": \"72888-033\",\n \"UpdatedDate\": \"Nov 23, 2021\",\n \"LabelSource\": {\n \"LabelTitle\": \"AMANTADINE HYDROCHLORIDE - amantadine hydrochloride capsule Advagen Pharma Limited\",\n \"TradeName\": \"Amantadine Hydrochloride\",\n \"Manufacturer\": \"Advagen Pharma Limited\",\n \"Country\": \"us\",\n \"ProductId\": \"c3b9e7f0-be6d-4f37-9277-54bb0ba8b158\",\n \"FileId\": \"d124ff30-7360-4446-e053-2995a90af5ff\",\n \"Version\": \"4\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3b9e7f0-be6d-4f37-9277-54bb0ba8b158\",\n \"genericNames\": \"amantadine hydrochloride\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n },\n {\n \"Id\": \"USd4595cc8-7960-6c44-e053-2995a90adb3e\",\n \"NDCCode\": \"24689-105\",\n \"UpdatedDate\": \"Jan 21, 2022\",\n \"LabelSource\": {\n \"LabelTitle\": \"AMANTADINE HYDROCHLORIDE - amantadine hydrochloride capsule APNAR PHARMA LP\",\n \"TradeName\": \"AMANTADINE HYDROCHLORIDE\",\n \"Manufacturer\": \"APNAR PHARMA LP\",\n \"Country\": \"us\",\n \"ProductId\": \"d4595cc8-795f-6c44-e053-2995a90adb3e\",\n \"FileId\": \"d4595cc8-7960-6c44-e053-2995a90adb3e\",\n \"Version\": \"1\",\n \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4595cc8-795f-6c44-e053-2995a90adb3e\",\n \"genericNames\": \"amantadine hydrochloride\"\n },\n \"AdverseEventTerms\": null,\n \"IndicationTerms\": null\n }\n ]\n }\n ]\n}"}],"_postman_id":"d3d6b6ed-c1ab-4753-968e-f0c527fc6928"}],"auth":{"type":"basic","basic":{"basicConfig":[{"key":"username","value":"<username>"},{"key":"password","value":"<password>"}]}},"event":[{"listen":"prerequest","script":{"id":"864fe197-4f8c-4686-b767-16059bdb88dc","type":"text/javascript","exec":[""]}},{"listen":"test","script":{"id":"a8445ed3-872e-40aa-ad3f-ec26a349bf28","type":"text/javascript","exec":[""]}}],"variable":[{"key":"uniquelabelid","value":"US3f5d8caf-a587-4c9f-85a7-f74935acc991"}]}